

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C. 20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 17 August 1999 (17.08.99)	Applicant's or agent's file reference 6056-236 PC
International application No. PCT/US98/16719	Priority date (day/month/year) 15 August 1997 (15.08.97)
International filing date (day/month/year) 13 August 1998 (13.08.98)	
Applicant NIEWIAROWSKI, Stefan et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
22 February 1999 (22.02.99)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Form PCT/IB/331 (July 1992)

Authorized officer

P. Regis

Telephone No.: (41-22) 338.83.38

2792969

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 14 OCT 1999

WIPO PCT

Applicant's or agent's file reference 6056-236 PC	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US98/16719	International filing date (day/month/year) 13 AUGUST 1998	Priority date (day/month/year) 15 AUGUST 1997
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant <u>NIEWIAROWSKI, STEFAN</u> TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 6 sheets.

- ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 22 FEBRUARY 1999	Date of completion of this report 24 SEPTEMBER 1999
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer GABRIELE E. BUGAISKY 
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/16719

I. Basis of the report

1. This report has been drawn on the basis of (*Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments*):

- ☒ the international application as originally filed.
- ☒ the description, pages 1-50 , as originally filed.
pages NONE , filed with the demand.
pages NONE , filed with the letter of _____.
pages _____ , filed with the letter of _____.
- ☒ the claims, Nos. 1-33 , as originally filed.
Nos. NONE , as amended under Article 19.
Nos. NONE , filed with the demand.
Nos. NONE , filed with the letter of _____.
Nos. _____ , filed with the letter of _____.
- ☒ the drawings, sheets/~~fig~~ 1-12 , as originally filed.
sheets/~~fig~~ NONE , filed with the demand.
sheets/~~fig~~ NONE , filed with the letter of _____.
sheets/~~fig~~ _____ , filed with the letter of _____.

2. The amendments have resulted in the cancellation of:

- ☒ the description, pages NONE .
- ☒ the claims, Nos. NONE .
- ☒ the drawings, sheets/~~fig~~ NONE .

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the ~~Supplemental Box~~ Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/16719

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. STATEMENT**

Novelty (N)	Claims <u>1-3, 5, 7-21, 23-33</u>	YES
	Claims <u>4, 6, 22</u>	NO
Inventive Step (IS)	Claims <u>1-3, 5, 7-21, 23-33</u>	YES
	Claims <u>4, 6, 22</u>	NO
Industrial Applicability (IA)	Claims <u>1-33</u>	YES
	Claims <u>NONE</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 1-3, 5, 7-20, 23 and 31-33 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the EC3 protein from *Echis carinatus* venom, pharmaceuticals containing EC3, constructs containing the genes encoding the subunits of EC3 or hybridomas producing antibodies specific for EC3. Applicants have defined the disintegrin properties of EC3 and shown that it selectively inhibits binding of the $\alpha 4\beta 1$ and $\alpha 4\beta 7$ integrins to their ligands.

Claims 21 and 24-30 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the specific purification of peptides from venom using specific integrins or treatment of patients with EC3 to inhibit interactions of $\alpha 4$ integrins with other proteins.

Claims 4, 6, and 22 lack novelty under PCT Article 33(2) as being anticipated by glycine (The Merck Index). Glycine is anticipatory as it is a biologically active fragment of SEQ ID NO:2 and SEQ ID NO:3, and has been used as a pharmaceutical.

Claims 1-33 meet the criteria set out in PCT Article 33(4), for industrial applicability.

----- NEW CITATIONS -----

The Merck Index. "An Encyclopedia of Chemicals and Drugs". Eighth Edition. Edited by P. Stecher et al. Rahway, NJ: Merck & Co., Inc. 1968, page 500.

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/16719

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

The description is objected to as containing the following defect(s) under PCT Rule 66.2(a)(iii) in the form or contents thereof: The use of the trademark TRITON X-100 has been noted in this application, e.g., page 27, line 18 and page 33, line 15. It should be capitalized wherever it appears and be accompanied by the generic terminology. Although the use of trademarks is permissible, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks.

THIS PAGE BLANK (USPTO)

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The description is objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 5 because it fails to adequately enable practice of the claimed invention because:

While being enabling for EC-3 and DNA constructs encoding the EC -3A and EC-3B peptides, the description does not reasonably provide enablement for derivatives or homolog which have substantial homology and the ability to inhibit adhesion of cells thereof or for nucleic acids encoding such variants or homologs. The description further provides no mutants and minimal guidance as to where the mutations may occur. There is no predictability as to which residues may be substituted so that the encoded protein(s) still acts like EC-3.

There are eight factors to be considered in a determination of "undue experimentation". These factors include: (a) the quantity of experimentation necessary; (b) the amount of direction or guidance presented; (c) the presence or absence of working examples; (d) the nature of the invention; (e) the state of the prior art; (f) the relative skill of those in the art; (g) the predictability of the art; and (h) the breadth of the claims. Although the level of skill in molecular biology is high, results of experiments in molecular biology are unpredictable.

Since the amino acid sequence of a protein determines its structural and functional properties, predictability of which changes can be tolerated in a protein's amino acid sequence and retain or achieve the desired activity requires a knowledge of and guidance with regard to which amino acids in the protein's sequence, if any, are tolerant of modification and which are conserved (i.e. expectedly intolerant to modification), and detailed knowledge of the ways in which the protein's structure relates to its function.

One skilled in the art would expect any tolerance to modification shown for a given protein to diminish with each further and additional modification, e.g. multiple substitutions. The description does not disclose the following: (A) the general tolerance to modification and extent of such tolerance; (B) which regions are critical for biological activity; (C) what fragments, if any, can be made which have the desired biological activity of the intact protein; and (D) the description provides insufficient guidance as to which of the essentially infinite possible choices is likely to be successful.

While recombinant and mutagenesis techniques are known, it is not routine in the art to screen for multiple substitutions or multiple modifications, or to screen for the other positions within the protein's sequence where amino acid modifications can (Continued on Supplemental Sheet.)

THIS PAGE BLANK (USPTO)

Supplemental B x

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(6): A61K 38/04, 38/17, 48/00; C07K 1/36, 4/12, 5/08, 5/10, 7/04, 14/46, 16/18; C12N 1/00, 5/10, 5/12, 15/12, 15/63; G01N 33/50 and US Cl.: 435/7.21, 334, 325, 252.3, 320.1; 530/324, 326, 327, 328, 329, 344, 350, 387.9, 412, 415; 536/23.5

VIII. CERTAIN OBSERVATIONS ON THE APPLICATION (Continued):

be made with a reasonable expectation of success in obtaining the desired activity/utility; the result of such modifications is highly unpredictable. No derivatives have been provided, and there is no way to predict where one may profitably make variants which encode homologs that retain distintegrin activity.

Claims 4, 6, 13-19, and 22-33 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because practice of the claimed invention is not enabled as required under PCT Rule 5.1(a) for the reasons set forth in the immediately preceding paragraph.

The description is objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 5 because it fails to adequately enable practice of the claimed invention because: it does not identify which patients require treatment to inhibit the interaction of $\alpha 4$ integrins with specific ligands, nor does it provide a specific protocol for treatment. While the description states on p 4, lines 17-24 that activation and up-regulation of $\alpha 4\beta 1$ or $\alpha 4\beta 7$ on lymphocytes and macrophages is believed to play a significant role in the progression of many disease states; however, no therapies are provided, and the contemplated dosage range of 0.001 mg/kg-100mg/kg is so broad so to be essentially useless. One has been presented with an invitation to experiment in order to try to determine a treatment method with EC3 peptides that will inhibit the interaction of $\alpha 4$ integrins with specific ligands.

Claims 28-30 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because practice of the claimed invention is not enabled as required under PCT Rule 5.1(a) for the reasons set forth in the immediately preceding paragraph.

Claims 1-20 and 22-33 are objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because the claims are indefinite for the following reason(s): Claims 1-6, 8, 13, 20, and 31-33 recite the term "substantially purified". The description defines the term on p. 15, lines 1-9 as "substantially free of those compounds that are normally associated with. . ." The metes and bounds of the claims are not clear because the degree of purity that "substantially" encompasses has not been defined. Claims 7, 9-12, 14-19 and 22-30 are included in this objection as they read from the above claims and do not clarify the ambiguity.

Claims 13-15, 23 and 33 are objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because the claims is indefinite for the following reason(s): There is no art recognized high stringency condition; it is well known that these need to be experimentally determined for each set of nucleic acids to be hybridized. The definition of "stringent conditions" on page 16, lines 19-23 is noted; however, only a single non-limiting example is given, and the claims do not specify any specific condition. Claims 14-15 are included in this objection as they read from claim 13 and do not clarify the ambiguity.

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/16719

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.21, 334, 325, 331, 252.3, 320.1; 530/324, 326, 327, 328, 329, 344, 350, 387.9, 388.2, 412, 415, 856; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SIIGUR et al. cDNA Cloning and Deduced Amino Acid Sequence of Fibrinolytic Enzyme (Lebetase) from Vipera lebetina Snake Venom. Biochemical and Biophysical Research Communications. 1996, Vol. 224, No. 1, pages 229-336, especially figure 2.	1-15, 20, 22-23, 31-33
A	US 5,318,899 A (SCARBOROUGH et al.) 07 June 1994, entire document.	1-33

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

06 NOVEMBER 1998

Date of mailing of the international search report

31 DEC 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

GABRIELE E. BUGAISKY

Telephone No. (703) 308-0196

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/16719

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

A61K 38/04, 38/17, 48/00; C07K 1/36, 4/12, 5/08, 5/10, 7/04, 14/46, 16/18; C12N 1/00, 5/10, 5/12, 15/12, 15/63; G01N 33/50

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

435/7.21, 334, 325, 252.3, 320.1; 530/324, 326, 327, 328, 329, 344, 350, 387.9, 412, 415; 536/23.5

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN-CAS files registry, caplus, medline, wpids; A-Geneseq32, PIR56; SWISS-PROT35
search terms: Echis, coloratus, integrin?, alpha4, alpha 4, CS1, CS 1, MadCam, disintegrin?, screen?, echistatin, venom?, substitut?, mutat?, mutan?, jurkat, v cam, 66aa, 67aa, (66 or 67)(w)(amino acids or aa), nsvhpcdpv/sqsp, hpcdpv/sqsp, peptide?, viper, snake


THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/04, 38/17, 48/00, C07K 1/36, 4/12, 5/08, 5/10, 7/04, 14/46, 16/18, C12N 1/00, 5/10, 5/12, 15/12, 15/63, G01N 33/50	A1	(11) International Publication Number: WO 99/13898 (43) International Publication Date: 25 March 1999 (25.03.99)
--	-----------	--

<p>(21) International Application Number: PCT/US98/16719</p> <p>(22) International Filing Date: 13 August 1998 (13.08.98)</p> <p>(30) Priority Data:</p> <table><tr><td>60/055,825</td><td>15 August 1997 (15.08.97)</td><td>US</td></tr><tr><td>60/055,957</td><td>18 August 1997 (18.08.97)</td><td>US</td></tr></table> <p>(71)(72) Applicants and Inventors: NIEWIAROWSKI, Stefan [US/US]; 445 Woodbine Avenue, Narberth, PA 19072 (US). MARCINKIEWICZ, Cezary [PL/US]; 4517 Mitchell Street, Philadelphia, PA 19128 (US).</p> <p>(74) Agent: MONACO, Daniel, A.; Seidel, Gonda, Lavorgna & Monaco, P.C., Suite 1800, Two Penn Center Plaza, Philadelphia, PA 19102 (US).</p>	60/055,825	15 August 1997 (15.08.97)	US	60/055,957	18 August 1997 (18.08.97)	US	<p>(81) Designated State: US.</p> <p>Published</p> <p><i>With international search report. Upon request of the applicant under Article 64(3)(c)(i). Under Rule 91.1(f), with a request for rectification.</i></p>
60/055,825	15 August 1997 (15.08.97)	US					
60/055,957	18 August 1997 (18.08.97)	US					

(54) Title: EC-3, AN INHIBITOR OF $\alpha 4\beta 1$ AND $\alpha 4\beta 7$ INTEGRINS

(57) Abstract

The invention relates to the identification, purification, and characterization of a novel heterodimeric disintegrin, EC-3, from *Echis carinatus* viper venom. EC-3 inhibits $\alpha 4$ integrins in an RGD-independent manner. The invention further relates to methods of using EC-3, or a biologically active fragment or derivative thereof, to inhibit the interaction between cells expressing $\alpha 4$ integrins and cellular ligands.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

EC-3, AN INHIBITOR OF $\alpha 4\beta 1$ AND $\alpha 4\beta 7$ INTEGRINS**Cross-Reference to Related Applications**

This application claims the benefit of United States Provisional Application Serial No. 60/055,825, filed 15 August 1997, and United States
5 Provisional Application Serial No. 60/055,957, filed 18 August 1997.

Reference to Government Grant

The invention described herein was made, in part, in the course of work supported by the National Institutes of Health under Grant Nos. HL 45486 and HL 19055. The government has certain rights in the invention.

10

Field of the Invention

This invention generally relates to methods and compositions for modulating cell adhesion and for inhibiting the interaction between integrins and their ligands. In particular, the invention relates to peptides that selectively inhibit $\alpha 4$ integrins.

15

Background of the Invention**A. Integrins**

Integrins are a family of cell surface proteins that mediate adhesion between cells (cell-cell adhesion) and between cells and extracellular matrix proteins (cell-ECM adhesion). Integrins are heterodimeric structures composed
20 of noncovalently bound α and β subunits. In humans there are at least 15

different α and eight different β subunits, and these can combine to form proteins with diverse biological activities and ligand specificities.

The integrins play important roles in many diverse biological processes including platelet aggregation, tissue repair, angiogenesis, bone
5 destruction, tumor invasion, inflammation, and immune reactions. The integrins are, therefore, important targets for therapeutic intervention in human disease.

Integrin $\alpha\text{IIb}\beta 3$ (glycoprotein IIb/IIIa complex) binds fibrinogen on the platelet surface and mediates platelet aggregation. Integrin $\alpha\text{v}\beta 3$ is predominantly expressed on endothelial cells and plays an important role in
10 angiogenesis. Integrin $\alpha\text{v}\beta 3$ is also expressed on osteoclasts and participates in bone destruction. Integrin $\alpha 5\beta 1$ is widely distributed on a variety of cells; it plays a critical role in cell adhesion to extracellular matrix as well as in the formation of tissues and organs during embryonic development. All three integrins $\alpha\text{IIb}\beta 3$, $\alpha\text{v}\beta 3$ and $\alpha 5\beta 1$ recognize RGD sequences in the adhesive
15 ligands.

One example of the therapeutic targeting of integrins is the use of integrin inhibitors as antithrombotic agents. Peptides and peptidomimetics that block the adhesion of GPIIb/IIIa to fibrinogen can prolong bleeding times and prevent thrombotic occlusion *in vivo*. One group of naturally occurring peptides
20 that inhibit platelet aggregation by interfering with fibrinogen binding to GPIIb/IIIa has been called the "disintegrins."

B. Disintegrins

The disintegrins are a family of low molecular weight cysteine-rich peptides that have been isolated from the venom of various snakes (reviewed in
25 Niewiarowski *et al.*, *Seminars in Hematology* **31**(4):289-300 (1994)). Most disintegrins described to date contain an RGD motif. RGD is a recognition site for many integrins, and disintegrins inhibit fibrinogen binding to GPIIb/IIIa, as well as the binding of other ligands to RGD-dependant integrins on the surface of cells. Peptides modeled on the structure of disintegrins have potential clinical

- 3 -

applications in the prevention and treatment of coronary thrombosis, stroke, and other vascular diseases.

The first disintegrin described in the literature, trigramin, was identified and characterized on the basis of its ability to block platelet aggregation and inhibit fibrinogen binding to $\alpha\text{IIb}\beta 3$. Trigramin contains 72 amino acids including 12 cysteines, is linked by S-S bonds, and contains an RGD sequence. Subsequently several other RGD containing viper venom disintegrins of similar size were isolated.

A 49 amino acid disintegrin, called echistatin, has been isolated from the venom of *Echis carinatus* (Gan *et al.*, *J. Biol. Chem.* **263**:19827-32 (1988)). Like other disintegrins, echistatin contains an RGD sequence and inhibits GPIIb/IIIa binding of fibrinogen. Echistatin has been called a "promiscuous disintegrin" because it blocks $\alpha\text{IIb}\beta 3$, $\alpha\text{v}\beta 3$ and $\alpha 5\beta 1$ with similar potency.

NMR studies on RGD-containing disintegrins shows that the RGD sequence is located in a mobile loop joining two strands of β sheet protruding from the protein core (reviewed in Niewiarowski *et al.*, *Semin. Hematol.* **31**:289-300 (1994)). The disulfide bonds around the RGD sequence maintain the hair-pin loop conformation in each peptide, and this conformation seems to be important for potency and selectivity.

The disintegrin eristostatin, originally described as a potent inhibitor of $\alpha\text{IIb}\beta 3$, also inhibits human melanoma cell (MV3) metastases in immune deficient mice. It has been suggested that this effect is mediated by altering the function of an $\alpha 4$ integrin expressed on MV3 cells (Danen *et al.*, *Exp. Cell Res.* **238**:188-196 (1998)).

C. The $\alpha 4$ Integrins

The $\alpha 4$ integrins, $\alpha 4\beta 1$ and $\alpha 4\beta 7$, are expressed on leukocytes and lymphoid cells, and play a major role in inflammation and auto-immune diseases.

- 4 -

The $\alpha 4\beta 1$ integrin (which has also been called VLA-4, very late activation antigen 4) mediates cell adhesion to vascular cell adhesion molecule-1 (VCAM-1), an adhesive molecule belonging to the IgG superfamily which is expressed on endothelial cells at sites of inflammation. The integrin $\alpha 4\beta 1$ also binds to alternatively spliced variants of fibronectin containing connecting segment 1 (CS-1).

The $\alpha 4\beta 7$ integrin binds to the gut homing receptor mucosa addressin cell adhesion molecule-1 (MadCAM-1) and to a lesser extent to CS-1 and VCAM-1.

Cytokine activated leukocytes express $\alpha 4\beta 1$ and $\alpha 4\beta 7$ integrins. Interaction of these integrins with VCAM-1 or MadCAM-1 (which are also up-regulated by cytokines) on endothelium mediates capillary infiltration by leukocytes, which can lead to tissue and organ destruction. Selectins and $\beta 2$ integrins also contribute to this process. Altevost *et al.* reported that the $\alpha 4$ subunit itself is a ligand for $\alpha 4\beta 1$ and $\alpha 4\beta 7$ integrins (*J. Exp. Med.* **182**:345-55 (1995)), suggesting that $\alpha 4$ integrins may play a role in leukocyte communication during the immune response.

Activation and up-regulation of $\alpha 4\beta 1$ or $\alpha 4\beta 7$ on lymphocytes or macrophages is believed to play a significant role in the progression of many disease states, including insulin dependent diabetes mellitus, multiple sclerosis, rheumatoid arthritis, ulcerative colitis, arteriosclerosis, asthma, allergy, organ rejection, and restenosis of arteries after surgery or angioplasty. The $\alpha 4$ integrins are therefore targets for therapeutic intervention in a variety of inflammatory, auto-immune, and other diseases.

D. The $\alpha 4$ Integrins as Therapeutic Targets

There are several animal models of inflammatory and autoimmune diseases in which endothelial infiltration by lymphocytes and organ destruction are blocked by anti- $\alpha 4$ monoclonal antibodies. As an example, anti- $\alpha 4$ antibody inhibits lymphocyte infiltration of Langerhans islets in NOD mice, thus

preventing development of spontaneous insulin dependent diabetes (Yang *et al.*, *Proc. Natl. Acad. Sci. USA* **91**:12604-08 (1994)). Anti- $\alpha 4$ monoclonal antibodies have also shown *in vivo* efficacy in animal models of asthma (Abraham *et al.*, *J. Clin. Invest.* **93**:776 (1994)), multiple sclerosis (Yednock *et al.*, *Nature* **356**:63 (1992)), inflammatory bowel disease (Podolsky *et al.*, *J. Clin. Invest.* **92**:372 (1993)), contact hypersensitivity (Chisholm *et al.*, *Eur. J. Immunol.* **23**:682 (1993)), and cardiac allograft rejection (Isobe *et al.*, *J. Immunol.* **153**:5810 (1994)).

There have been several attempts to isolate naturally occurring or to develop synthetic inhibitors of $\alpha 4\beta 7$ and $\alpha 4\beta 1$. Synthetic inhibitors that have been reported include cyclic RGD peptides and short peptides based on the sequences of MadCAM-1, VCAM-1, and CS-1. These peptides are typically active *in vitro* at the micromolar level.

Molossi *et al.* (*J. Clin. Invest.* **95**:2601-10 (June 1995)) reported that blockade of $\alpha 4\beta 1$ (VLA-4) integrin binding to fibronectin with CS-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts. The sequence of the CS-1 peptide was phenylacetic acid-Leu-Asp-Phe-d-Pro-amide.

Kogan *et al.* (WO 96/00581) reported that cyclic peptides modeled after a portion of the CS-1 peptide inhibited the binding of $\alpha 4\beta 1$ integrin to VCAM-1 at concentrations of peptide less than about 10 μM .

Kogan *et al.* (U.S. Patent No. 5,510,332) reported that a peptide comprising the LDV domain of CS-1 peptide inhibited the binding of $\alpha 4\beta 1$ integrin to VCAM-1 with an IC_{50} of 30 μM .

Shroff *et al.* (*Bioorganic and Medicinal Chemistry Letters* **6**(21):2495-2500 (1996)) reported a series of peptides based on the N-terminal domain of MAdCAM-1 inhibited the binding of HUT78 cells activated with Mn^{++} to MAdCAM-1 with an IC_{50} of 5 to >1000 μM . Cyclic peptides based on an N-terminal conserved motif in VCAM-1 have also been reported to inhibit VCAM/ $\alpha 4\beta 1$ mediated leukocyte adhesion (Wang *et al.*, *Proc. Natl. Acad. Sci. USA* **92**:5714 (1995)).

- 6 -

Cyclic RGDS (SEQ ID NO:15) peptides have been reported as strong inhibitors of $\alpha 4\beta 1$ and $\alpha 4\beta 7$ integrins (Cardarelli *et al.*, *J. Biol. Chem.* **269**:18668-73 (1994); Yang *et al.* *Eur. J. Immunol.* **28**:995-1004 (1998)).

Vanderslice *et al.* (*J. Immunol.* **158**:1710-18 (1997)) recently
5 reported that a cyclic peptide based on the LDV sequence of CS-1 inhibited $\alpha 4\beta 1$ dependent binding of lymphocytes to VCAM and CS-1 with an IC_{50} of 1-3 μM .

There is a need for potent and specific inhibitors of $\alpha 4$ integrins, and for methods of specifically inhibiting the binding of $\alpha 4$ integrins to cellular ligands.

10

Summary of the Invention

The present invention relates to the discovery of the EC-3 protein, a heterodimeric disintegrin that is an extremely potent antagonist of $\alpha 4$ integrins. EC-3 proteins and peptides inhibit adhesion of cells expressing $\alpha 4$ integrins in
15 an RGD-independent manner.

The invention provides a substantially purified EC-3 protein, isolated from *E. carinatus* venom and characterized by: (a) an apparent molecular weight of about 14,762 Da, as determined by electrospray ionization mass spectrometry; (b) elution from a C-18 HPLC column at about 40%
20 acetonitrile; and (c) the ability to inhibit adhesion of Jurkat cells to VCAM-1.

The invention also provides a substantially purified EC-3A peptide, isolated from EC-3 protein which has been reduced and alkylated, and characterized by: (a) a molecular mass of about 8478 Da in its ethylpyridylated form, as determined by electrospray ionization mass spectrometry; (b) elution
25 from a C-18 HPLC column at about 42% acetonitrile; and (c) the ability to inhibit adhesion of K562 cells to fibronectin.

The invention further provides a substantially purified EC-3B peptide, isolated from EC-3 protein which has been reduced and alkylated with vinylpyridine, and characterized by: (a) a molecular mass of about 7950 Da in
30 its carboxymethylated form, as determined by electrospray ionization mass

- 7 -

spectrometry; (b) elution from a C-18 HPLC column at about 46% acetonitrile; and (c) the ability to inhibit adhesion of Jurkat cells to VCAM-1.

One preferred embodiment of the invention is a substantially purified EC-3A peptide comprising the sequence SEQ ID NO:19, or a
5 biologically active fragment or derivative thereof. A more preferred embodiment is a substantially purified peptide comprising the sequence SEQ ID NO:2, or a biologically active fragment or derivative thereof.

Another preferred embodiment of the invention is a substantially purified EC-3B peptide comprising the sequence SEQ ID NO:20, or a
10 biologically active fragment or derivative thereof. A more preferred embodiment is a substantially purified peptide comprising the sequence SEQ ID NO:3, or a biologically active fragment or derivative thereof.

A further embodiment of the invention is a substantially purified EC-3 protein comprising two subunits, wherein one subunit comprises the
15 sequence SEQ ID NO:19 or a biologically active fragment or derivative thereof and one subunit comprises the sequence SEQ ID NO:20 or a biologically active fragment or derivative thereof.

The invention is also directed to a biologically active peptide fragment of EC-3B having the sequence X-Y-Met-Leu-Asp-Z, where X is H or
20 a blocking group, Y is zero or more amino acids, and Z is OH or zero or more amino acids. In some preferred embodiments the biologically active peptide is from about 3 to about 20 amino acids. In a more preferred embodiment the peptide has the sequence SEQ ID NO:16. In another more preferred embodiment the peptide has the sequence SEQ ID NO:14.

25 Another aspect of the invention is a substantially purified nucleic acid encoding a protein or peptide according to the invention. One embodiment of the invention is a vector comprising a nucleic acid encoding a protein or peptide according to the invention. Another embodiment of the invention is a recombinant cell comprising a nucleic acid encoding a protein or peptide
30 according to the invention.

- 8 -

The invention further provides an antibody which specifically binds to a protein or peptide according to the invention. The antibody may be a monoclonal antibody or a polyclonal antibody or an antibody fragment that is capable of binding antigen. One aspect of the invention is a hybridoma that produces a monoclonal antibody which specifically binds to a protein or peptide according to the invention.

Another aspect of the invention is a substantially purified echistatin polypeptide in which the Arg-Gly-Asp residues at positions 24-26 are replaced by Met-Leu-Asp, or a biologically active fragment or derivative thereof.

The invention further provides a method of isolating a peptide that binds to an integrin of interest from venom comprising: (a) dissolving venom in a solvent, (b) centrifuging the dissolved venom to remove high molecular weight proteins, (c) fractionating the supernatant from step (b), (d) immobilizing the fractions from step (c) on a solid support, (e) adding detectably labeled cells which express the integrin of interest to the immobilized fractions, (f) detecting the number of cells bound to each immobilized fraction, and (g) isolating peptide from those fractions which showed enhanced cell binding in step (f).

Another aspect of the invention is a composition comprising a pharmaceutically acceptable carrier and a protein, peptide, or nucleic acid according to the invention.

The invention encompasses a method of inhibiting the binding of an $\alpha 4$ integrin to VCAM-1 comprising contacting a cell that expresses the $\alpha 4$ integrin with an effective amount of a protein or peptide according to the invention. In preferred embodiments the integrin is $\alpha 4\beta 1$ or $\alpha 4\beta 7$.

The invention also encompasses a method of inhibiting the binding of $\alpha 4\beta 7$ integrin to MadCAM-1 comprising contacting a cell that expresses $\alpha 4\beta 7$ with an effective amount of a protein or peptide according to the invention.

The invention further encompasses a method of inhibiting the binding of an $\alpha 4$ integrin to CS-1 comprising contacting a cell that expresses the

- 9 -

α 4 integrin with an effective amount of a protein or peptide according to the invention.

One preferred embodiment of the invention is a method of inhibiting the interaction between cells expressing an α 4 integrin and VCAM-1 in a patient in need of such treatment comprising administration of a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and a protein or peptide according to the invention.

Another preferred embodiment of the invention is a method of inhibiting the interaction between cells expressing an α 4 integrin and MadCAM-1 in a patient in need of such treatment comprising administration of a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and a protein or peptide according to the invention.

A further preferred embodiment of the invention is a method of inhibiting the interaction between cells expressing an α 4 integrin and CS-1 in a patient in need of such treatment comprising administration of a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and a protein or peptide according to the invention.

The invention is also directed to the use of a protein, peptide, or nucleic acid according to the invention for the preparation of a medicament for inhibiting the interaction between cells expressing an α 4 integrin and its ligands.

Other aspects and advantages of the present invention are described in the drawings and in the following detailed description of the preferred embodiments thereof.

Description of the Drawings

Figure 1 shows the HPLC fractionation of *E. carinatus* venom on a reverse phase C-18 HPLC column eluted with an acetonitrile gradient (dashed line). Fractions containing the disintegrin echistatin (EC1), the echicetin protein (which binds to GPIb/IX receptors on platelets, EC10) and EC3 are indicated.

- 10 -

Figure 2 shows the effect of selected fractions obtained from *Echis carinatus* venom on adhesion of Jurkat cells to immobilized VCAM-1 (Fig. 2A) and K562 cells to immobilized fibronectin (Fig. 2B).

Figure 3 shows the elution profile of reduced and alkylated EC-3 from a reverse phase HPLC column eluted with an acetonitrile gradient (dashed line). Fractions containing EC3A and EC3B are indicated.

Figure 4 shows the amino acid sequences of EC-3 subunits EC-3A (SEQ ID NOs:19 and 2; Fig. 4A) and EC-3B (SEQ ID Nos: 20 and 3; Fig. 4B), which were established by N-terminal sequencing of reduced and ethylpyridylethylated subunits and by sequencing of peptides isolated from digests with endoproteinase Lys-C. EC-3B was also digested by CNBr and two peptides were isolated.

Figure 5 shows a comparison of the amino acid sequence of EC3A (SEQ ID NO:2), EC3B (SEQ ID NO:3), with two short disintegrins eristostatin (SEQ ID NO:8) and echistatin (SEQ ID NO:9), with two medium size disintegrins flavoridin (SEQ ID NO:10) and kistrin (SEQ ID NO:11), and with a disintegrin domain of Le3 (SEQ ID NO:7), a metalloproteinase from *Vipera lebetina* venom. Boxes show the positions of conserved cysteine residues. The typical active site of the disintegrins (RGD) as well as the corresponding position in EC-3A(VGD), EC-3B (MLD), and Le3 (VGD) are underlined.

Figure 6 shows the effect of EC-3 on Jurkat cell adhesion to immobilized VCAM-1 in the presence (filled circles) or absence (open circles) of 1 mM Mn^{++} .

Figure 7 shows the effect of EC-3 on CHO ($\alpha 4+$, $\alpha 5-$) cell adhesion to immobilized VCAM-1.

Figure 8 shows the effect of EC3 on the adhesion of CHO cells transfected with different integrins. Adhesion experiments were performed using Chinese hamster ovary (CHO) cells transfected with different human integrins. Open circles show the effect of EC-3 on the adhesion of CHO cells transfected with $\alpha 4$ to immobilized VCAM-1; closed circles: CHO cells transfected with

- 11 -

α Ib β 3 to fibrinogen; open triangles: CHO cells transfected with α v β 3 to vitronectin; and closed triangles: non-transfected CHO cells expressing hamster α 5 β 1 to fibronectin. Error bars represent S.D. from three experiments.

Figure 9 shows the effect of RGD peptides and HP2/1 on Jurkat cell-EC-3 interactions. Figure 9A shows the effect of GRGDSP (SEQ ID NO:12), GRGESP (SEQ ID NO: 13) and HP 2/1 monoclonal antibody on the adhesion of Jurkat cells to immobilized EC-3. Figure 9B shows the effect of EC-3 on the binding HP 2/1 monoclonal antibody to cells expressing α 4 β 1 integrin. Error bars represent the S.D. from three experiments.

Figure 10 shows the adhesion of CHO cells transfected with α 4 and with α 4 inactive G190A mutant to immobilized EC-3 and to immobilized HP2/1 antibody. The number of adhered cells is shown for: (a) CHO cells transfected with wild-type α 4, (b) CHO cells transfected with G190A α 4, (c) control CHO-K1 cells. The results with EC-3 are shown as open bars, and the results with HP2/1 are shown as closed bars. Error bars represent S.D. from three experiments.

Figure 11 shows the effect of reduced and ethylpyridylethylated EC3A (open circles) and EC3B (closed circles) on adhesion of Jurkat cells to immobilized VCAM-1 (Fig. 11A) and K562 cells to immobilized fibronectin (Fig. 11B). Error bars indicate S.D. from three experiments.

Fig. 12 shows the effect of EC-3B derived peptides on Jurkat cell adhesion to immobilized VCAM-1. The inhibitory effect of MLDG peptide (SEQ ID NO: 14) is shown by open circles, RGDS peptide (SEQ ID NO: 15) by closed circles, cyclic *CKRAMLDGLNDYC* (SEQ ID NO: 16) by open triangles and *CKRAMLAGLNDYC* (SEQ ID NO: 17) by closed triangles. Error bars indicate S.D. from three experiments.

Detailed Description of the Invention

The present invention relates to the discovery of a novel protein, EC-3, which is a potent inhibitor of α 4 β 1 and α 4 β 7 integrins. The EC-3 protein

- 12 -

was purified from *Echis carinatus suchoreki* viper venom. EC-3 inhibits adhesion of cells expressing $\alpha 4\beta 1$ and $\alpha 4\beta 7$ integrins to natural ligands VCAM-1 and MadCAM-1 with $IC_{50} = 5-300$ nM. Its blocking activity resembles that of some monoclonal antibodies but is 2 to 3 orders of magnitude higher than most synthetic antagonists. The EC-3 inhibitory effect is not RGD dependent but is competed by HP 2/4 and HP 2/1 monoclonal antibodies, which recognize epitopes on $\alpha 4$.

EC-3 comprises two types of subunits, EC-3A and EC-3B, which are covalently linked. The EC-3A and EC-3B subunits show a high degree of homology with other viper venom disintegrins, including the alignment of conserved cysteines. The conserved RGD motif of integrins is replaced, however, by VGD in EC-3A and by MLD in EC-3B.

A. Abbreviations and Short Forms

The following abbreviations and short forms are used in this specification.

"BSA" is bovine serum albumin.

"CHO cells" are Chinese hamster ovary cells.

"CMFDA" is 5-chloromethylfluorescein diacetate.

"CS-1" is connecting segment 1 of fibronectin.

"DBA" is direct binding assay.

"EC-3 protein" (also called EC3 protein) is a heterodimeric protein comprising an EC-3A (also called EC3A) subunit and an EC-3B (also called EC3B) subunit. The term "EC-3 peptide" (also called EC3 peptide) as used herein encompasses the EC-3 protein as well as the EC-3A and EC-3B subunits, and fragments thereof.

"ECM" is extracellular matrix.

"ep" is ethylpyridylethylated. The ethylpyridylethylated forms of EC-3A and EC-3B are designated "epEC3A" and "epEC3B."

"HBSS" is Hanks' balanced salt solution.

- 13 -

"HPLC" is high performance liquid chromatography.

"Ig" is immunoglobulin.

"IC₅₀" is the concentration of a biologically active agent such as a peptide, which inhibits 50% of the activity obtained in the absence of the agent.

5 "Mab" is monoclonal antibody.

"MadCAM-1" is mucosal addressin cell adhesion molecule-1, a member of the IgG protein superfamily having a mucin component. MadCAM-1 is a cellular ligand for the $\alpha 4\beta 7$ integrin.

10 "MLD" is the one letter designation of the amino acid sequence Met-Leu-Asp, which occurs in the EC-3 protein.

"NOD mouse" is a Non Obese Diabetic mouse.

"PBS" is phosphate buffered saline solution.

15 "RGD" is the one letter designation for the amino acid sequence Arg-Gly-Asp. RGD is a recognition site for many disintegrins. A related recognition site is "KGD" which is the one letter designation for Lys-Gly-Asp.

"TFA" is trifluoroacetic acid.


"VCAM-1" is vascular cell adhesion molecule-1, a member of the IgG protein superfamily which is a cellular ligand for the $\alpha 4\beta 1$ and $\alpha 4\beta 7$ integrins.

20 "VLA-4" is very late activation antigen 4.

B. Definitions

The following definitions, of terms used throughout the specification, are intended as an aid to understanding the scope and practice of the present invention.

25 A "peptide" is a compound comprised of amino acid residues covalently linked by peptide bonds. Amino acids have the following general structure:



- 14 -

Amino acids are classified into seven groups on the basis of the side chain R: (1) aliphatic side chains, (2) side chains containing a hydroxylic (OH) group, (3) side chains containing sulfur atoms, (4) side chains containing an acidic or amide group, (5) side chains containing a basic group, (6) side chains containing an aromatic ring, and (7) proline, an imino acid in which the side chain is fused to the amino group. Peptides comprising a large number of amino acids are sometimes called "**polypeptides**". The EC-3A and EC-3B subunits of EC-3 are peptides.

A "**protein**" is a polypeptide which plays a structural or functional role in a biological system. Proteins comprise one or more peptides. EC-3 is a protein.

"**Fibrinogen**" is a blood plasma glycoprotein, which is involved in platelet aggregation and fibrin formation.

"**Integrins**" are a family of heterodimeric cell surface proteins which mediate adhesion between cells and between cells and extracellular matrix proteins.

"**Disintegrins**" are a family of peptides isolated from snake venoms which inhibit the binding of various ligands to integrins.

"**Echistatin**" is a 49 amino acid disintegrin isolated from *Echis carinatus* venom.

"**Homology**" means similarity of sequence reflecting a common evolutionary origin. Peptides or proteins are said to have homology, or similarity, if a substantial number of their amino acids are either (1) identical, or (2) have a chemically similar R side chain. Nucleic acids are said to have homology if a substantial number of their nucleotides are identical.

"**Substantial amino acid sequence homology**" means an amino acid sequence homology greater than about 30 percent, preferably greater than about 60%, more preferably greater than about 80%, and most preferably greater than about 90 percent.

- 15 -

"**Substantially purified peptide**" or "**substantially purified protein**" means a peptide or protein which is substantially free of those compounds that are normally associated therewith in its natural state (*e.g.*, other proteins or peptides, nucleic acids, carbohydrates, lipids). "Substantially purified" is not meant to exclude artificial or synthetic mixtures with other compounds, or the presence of impurities which do not interfere with biological activity, and which may be present, for example, due to incomplete purification, addition of stabilizers, or compounding into a pharmaceutically acceptable preparation.

10 A "**biologically active fragment**" of an EC-3 peptide is a fragment derived from an EC-3 peptide which retains at least one biological activity of the EC-3 peptide.

 A "**biologically active derivative**" of an EC-3 peptide is any analogue, variant, derivative, or mutant which is derived from an EC-3 peptide, which has substantial amino acid sequence homology with the EC-3 peptide, and which retains at least one biological property of the EC-3 peptide. Different variants of EC-3 peptides may exist in nature. These variants may be allelic variations characterized by differences in the nucleotide sequences of the structural gene coding for EC-3 peptides, or may involve differential splicing or post-translational modification. The skilled artisan can produce derivatives having single or multiple amino acid substitutions, deletions, additions, or replacements. These derivatives may include, *inter alia*: (a) derivatives in which one or more amino acid residues are substituted with conservative or non-conservative amino acids, (b) derivatives in which one or more amino acids are added to an EC-3 peptide, (c) derivatives in which one or more of the amino acids includes a substituent group, and (d) derivatives in which the EC-3 peptide is fused with another peptide such as serum albumin. The techniques for obtaining these derivatives, including genetic (suppressions, deletions, mutations, etc.), chemical, and enzymatic techniques, are known to persons having ordinary skill in the art.

15
20
25
30

- 16 -

Biologically active fragments and biologically active derivatives of EC-3 peptides are intended to be included within the scope of this invention.

A "**blocking group**" is any group capable of blocking the N-terminal amino group of a peptide. A preferred blocking group is an alkyl group;
5 a most preferred blocking group is an acetyl group.

A "**nucleic acid**" is a polymeric compound comprised of covalently linked subunits called nucleotides. Nucleic acid includes polyribonucleic acid (RNA) and polydeoxyribonucleic acid (DNA), both of which may be single-stranded or double-stranded. DNA includes cDNA, genomic
10 DNA, synthetic DNA, and semi-synthetic DNA. The sequence of nucleotides that encodes a protein is called the sense sequence.

"**Isolated nucleic acid**" means a nucleic acid which is substantially free of those compounds that are normally associated therewith in its natural state. "Isolated" is not meant to exclude artificial or synthetic mixtures with
15 other compounds, or the presence of impurities which do not interfere with biological activity, and which may be present, for example, due to incomplete purification, addition of stabilizers, or compounding into a pharmaceutically acceptable preparation.

The phrase "**a nucleic acid which hybridizes at high stringency**"
20 means that the hybridized nucleic acids are able to withstand a washing under high stringency conditions. An example of high stringency washing conditions for DNA-DNA hybrids is 0.1X SSC, 0.5% SDS at 68°C. Other conditions of high stringency washing are known to persons having ordinary skill in the art.

"**Regulatory region**" means a nucleic acid sequence which
25 regulates the expression of a nucleic acid. A regulatory region may include sequences which are naturally responsible for expressing a particular nucleic acid (a homologous region) or may include sequences of a different origin (responsible for expressing different proteins or even synthetic proteins). In particular, the sequences can be sequences of eukaryotic or viral genes or derived sequences
30 which stimulate or repress transcription of a gene in a specific or non-specific

- 17 -

manner and in an inducible or non-inducible manner. Regulatory regions include origins of replication, RNA splice sites, enhancers, transcriptional termination sequences, signal sequences which direct the polypeptide into the secretory pathways of the target cell, and promoters.

5 A regulatory region from a "**heterologous source**" is a regulatory region which is not naturally associated with the expressed nucleic acid. Included among the heterologous regulatory regions are regulatory regions from a different species, regulatory regions from a different gene, hybrid regulatory sequences, and regulatory sequences which do not occur in nature, but which are designed
10 by one having ordinary skill in the art.

 "**Operatively linked to a regulatory region**" means that the peptide or polypeptide coding region is connected to transcriptional and translational regulatory sequences in such a way as to permit polypeptide expression when the appropriate molecules (such as activator proteins and
15 polymerases) are present in a cell or cell free system.

 A "**vector**" is any means for the transfer of a nucleic acid according to the invention into a host cell. The term "vector" includes both viral and nonviral means for introducing the nucleic acid into a prokaryotic or eukaryotic cell *in vitro*, *ex vivo*, or *in vivo*. Non-viral vectors include plasmids,
20 liposomes, electrically charged lipids (cytofectins), DNA-protein complexes, and biopolymers. Viral vectors include retrovirus, adeno-associated virus, pox, baculovirus, vaccinia, herpes simplex, Epstein-Barr and adenovirus vectors. In addition to a nucleic acid according to the invention, a vector may also contain one or more regulatory regions, and/or selectable markers useful in selecting,
25 measuring, and monitoring nucleic acid transfer results (transfer to which tissues, duration of expression, etc.).

 A "**recombinant cell**" is a cell which contains a nucleic acid which is not naturally present in the cell. "Recombinant cell" includes higher eukaryotic cells such as mammalian cells, lower eukaryotic cells such as yeast
30 cells, prokaryotic cells, and archaeobacterial cells.

- 18 -

"Antibody" as used herein includes monoclonal and polyclonal antibodies as well as fragments capable of binding antigen, including but not limited to Fab and F(ab)₂ fragments.

5 "Pharmaceutically acceptable carrier" includes diluents and fillers which are pharmaceutically acceptable for methods of administration, may be sterile, and may be aqueous or oleaginous suspensions formulated using suitable dispersing or wetting agents and suspending agents. The particular pharmaceutically acceptable carrier and the ratio of active compound to carrier are determined by the solubility and chemical properties of the composition, the
10 particular mode of administration, and standard pharmaceutical practice.

C. Proteins and Peptides

The present invention provides substantially purified EC-3 peptides, including the EC-3 protein, the EC-3A and EC-3B peptides, and biologically active fragments and derivatives of EC-3, EC-3A, and EC-3B. The
15 invention also provides methods of isolation and peptides isolated from other venoms having biological activity similar to EC-3.

The peptides of the present invention may be recombinant peptides, natural peptides, or synthetic peptides. Each peptide is characterized by a reproducible single molecular weight and/or multiple set of molecular
20 weights, chromatographic response and elution profile, amino acid composition and sequence, and biological activity.

The peptides of the present invention may be isolated from natural sources, such as viper venom, using the methods disclosed herein.

The peptides of the invention may also be chemically synthesized,
25 using, for example, solid phase synthesis methods.

In conventional solution phase peptide synthesis, the peptide chain can be prepared by a series of coupling reactions in which the constituent amino acids are added to the growing peptide chain in the desired sequence. The use of various N-protecting groups, *e.g.*, the carbobenzyloxy group of the t-

- 19 -

butyloxycarbonyl group, various coupling reagents (*e.g.*, dicyclohexylcarbodiimide or carbonyldimidazole, various active esters, *e.g.*, esters of N-hydroxyphthalimide or N-hydroxy-succinimide, and the various cleavage reagents, *e.g.*, trifluoroacetic acid (TFA), HCl in dioxane, boron tris-
5 (trifluoroacetate) and cyanogen bromide, and reaction in solution with isolation and purification of intermediates is well-known classical peptide methodology. The preferred peptide synthesis method follows conventional Merrifield solid-phase procedures. See Merrifield, *J. Amer. Chem. Soc.* **85**:2149-54 (1963) and *Science* **50**:178-85 (1965). Additional information about the solid phase synthesis
10 procedure can be had by reference to the treatise by Steward and Young ("Solid Phase Peptide Synthesis," W.H. Freeman & Co., San Francisco, 1969, and the review chapter by Merrifield in *Advances in Enzymology* **32**:221-296, F.F. Nold, Ed., Interscience Publishers, New York, 1969; and Erickson and Merrifield, *The Proteins* **2**:255 *et seq.* (ed. Neurath and Hill), Academic Press, New York, 1976.
15 The synthesis of peptides by solution methods is described in Neurath *et al.*, eds. (*The Proteins*, Vol. II, 3d Ed., Academic Press, NY (1976)).

Crude peptides may be purified using preparative HPLC. The amino terminus may be blocked according, for example, to the methods described by Yang *et al.* (*FEBS Lett.* **272**:61-64 (1990)).

20 Peptide synthesis includes both manual and automated techniques employing commercially available peptide synthesizers. Fragments and derivatives of EC-3 peptides may be prepared by chemical synthesis and biological activity can be tested using the methods disclosed herein.

Alternatively, the peptides of the invention may be prepared
25 utilizing recombinant DNA technology, which comprises combining a nucleic acid encoding the peptide thereof in a suitable vector, inserting the resulting vector into a suitable host cell, recovering the peptide produced by the resulting host cell, and purifying the polypeptide recovered.

In some embodiments, the peptides of the present invention may
30 be used in the form of a pharmaceutically acceptable salt.

- 20 -

Suitable acids which are capable of forming salts with the peptides include inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like; and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid and the like.

Suitable bases capable of forming salts with the peptides include inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like; and organic bases such as mono-, di- and tri-alkyl and aryl amines (*e.g.*, triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like) and optionally substituted ethanol-amines (*e.g.*, ethanolamine, diethanolamine and the like).

D. Nucleic Acids

The present invention provides substantially purified nucleic acids which encode peptides according to the invention.

The techniques of recombinant DNA technology are known to those of ordinary skill in the art. General methods for the cloning and expression of recombinant molecules are described in Maniatis (*Molecular Cloning*, Cold Spring Harbor Laboratories, 1982), and in Sambrook (*Molecular Cloning*, Cold Spring Harbor Laboratories, Second Ed., 1989), and in Ausubel (*Current Protocols in Molecular Biology*, Wiley and Sons, 1987), which are incorporated by reference.

Having the EC-3A and EC-3B amino acid sequences disclosed herein, one of skill in the art can isolate or prepare a gene that encodes the peptide of interest. Synthetic genes may be synthesized directly on a DNA synthesizer, or may be synthesized as complementary oligonucleotides which are ligated together to form the synthetic gene. Alternatively, the native gene encoding the peptides of the invention may be isolated from genomic or cDNA

- 21 -

libraries. As an example, based upon the amino acid sequences disclosed herein, one of skill in the art can prepare suitable oligonucleotide probes and polymerase chain reaction (PCR) primers, which can be used to screen a cDNA library prepared from *E. carinatus* venom glands. Positive clones are purified and
5 sequenced to confirm their identity.

The nucleic acids encoding EC-3 peptides may be operatively linked to one or more regulatory regions. Regulatory regions include promoters, polyadenylation signals, translation initiation signals (Kozak regions), termination codons, peptide cleavage sites, and enhancers. The regulatory sequences used
10 must be functional within the cells of the vertebrate to be immunized. Selection of the appropriate regulatory region or regions is a routine matter, within the level of ordinary skill in the art.

Promoters that may be used in the present invention include both constitutive promoters and regulated (inducible) promoters. The promoters may
15 be prokaryotic or eukaryotic depending on the host. Among the prokaryotic (including bacteriophage) promoters useful for practice of this invention are lacI, lacZ, T3, T7, lambda P_r, P_L, and trp promoters. Among the eukaryotic (including viral) promoters useful for practice of this invention are ubiquitous promoters (*e.g.* HPRT, vimentin, actin, tubulin), intermediate filament promoters (*e.g.*
20 desmin, neurofilaments, keratin, GFAP), therapeutic gene promoters (*e.g.* MDR type, CFTR, factor VIII), tissue-specific promoters (*e.g.* actin promoter in smooth muscle cells), promoters which respond to a stimulus (*e.g.* steroid hormone receptor, retinoic acid receptor), tetracycline-regulated transcriptional modulators, cytomegalovirus immediate-early, retroviral LTR, metallothionein,
25 SV-40, E1a, and MLP promoters. Tetracycline-regulated transcriptional modulators and CMV promoters are described in WO 96/01313, US 5,168,062 and 5,385,839, the entire disclosures of which are incorporated herein by reference.

Examples of polyadenylation signals that can be used in the present
30 invention include but are not limited to SV40 polyadenylation signals and LTR

- 22 -

polyadenylation signals.

Fragments and derivatives of EC-3 peptides may be prepared using recombinant DNA technology. The biological activity of the fragments and derivatives can be assayed using the methods disclosed herein.

5 E. Antibodies

The present invention provides antibodies against EC-3 peptides. These antibodies may be monoclonal antibodies or polyclonal antibodies. The present invention includes chimeric, single chain, and humanized antibodies, as well as Fab fragments and the products of an Fab expression library.

10 Polyclonal antibodies may be generated against the intact protein or peptide, or against a fragment, derivative, or epitope of the protein or peptide. Antibodies may be obtained following the administration of the protein, polypeptide, fragment, derivative, or epitope to an animal, using the techniques and procedures known in the art.

15 Monoclonal antibodies may be prepared using the method of Mishell, B.B., *et al.*, *Selected Methods In Cellular Immunology*, (W.H. Freeman, ed.) San Francisco (1980). Briefly, a peptide of the present invention is used to immunize spleen cells of Balb/C mice. The immunized spleen cells are fused with myeloma cells. Fused cells containing spleen and myeloma cell
20 characteristics are isolated by growth in HAT medium, a medium which kills both parental cells, but allows the fused products to survive and grow.

Antibodies may be used to purify the peptides according to the invention, using immunoaffinity techniques which are well known by those of skill in the art.

25 F. Isolation of Related Peptides from Venoms

The present invention provides a method for isolating peptides that bind to an integrin of interest from the venom of snakes or other organisms. This method comprises the steps of:

- 23 -

- (a) dissolving venom in a solvent,
- (b) centrifuging the dissolved venom to remove high molecular weight proteins,
- (c) fractionating the supernatant from step (b),
- 5 (d) immobilizing the fractions from step (c) on a solid support,
- (e) adding detectably labeled cells which express the integrin of interest to the immobilized fractions,
- (f) detecting the number of cells bound to each
- 10 immobilized fraction, and
- (g) isolating peptide from those fractions which showed enhanced cell binding in step (f).

This method may be used to isolate peptides from the venom of species including but not limited to vipers and other snakes including *Agkistrodon*

15 *acutus*, *Agkistrodon halys blomhoffi*, *Agkistrodon contortrix mokasen*, *Bitis arietans*, *Bitis caudalis*, *Bitis gabonica*, *Bitis g. rhinoceros*, *Bothrops asper*, *Bothrops alternata*, *Bothrops atrox*, *Bothrops cotiara*, *Bothrops jararaca*, *Bothrops newiedi*, *Bothrops medusa*, *Bothrops schlegli*, *Cerastes cerastes*, *Cerastes vipera*, *Crotalus adamanteus*, *C. atrox*, *C. basilicus*, *C. durissus*

20 *totonatacus*, *C. h. horridus*, *C. m. molossus*, *C. ruber*, *C. scutalatus*, *C. v. cereberus*, *C. v. helleri*, *C. v. lutosus*, *C. v. oreganus*, *Echis carinatus sochurecki*, *Eristicophis macmahoni*, *Pseudocerastes persicus*, *Sistrurus m. barbouri*, *Sistrurus c. terqeminus*, *Trimeresurus flavoviridis*, *Trimeresurus gramineus*, *Vipera lebetina*, *Vipera ammondytes*, *Vipera palastinae*, and *Vipera*

25 *r. russelli*, leeches, ticks, and other organisms.

G. Methods of Treatment

The present invention provides methods of inhibiting the binding of $\alpha 4\beta 1$ or $\alpha 4\beta 7$ integrins to a ligand. A preferred embodiment is a method of inhibiting the interaction between cells expressing $\alpha 4\beta 1$ and/or $\alpha 4\beta 7$ integrins

- 24 -

and a ligand, in a patient in need of such treatment, comprising administration of a therapeutically effective amount of a composition comprising one or more peptides according to the invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. As an example, Non Obese Diabetic
5 mice treated with EC-3 show reduced levels of lymphocyte infiltration in pancreatic islets (see Example 7, below).

Pharmaceutically acceptable carriers include physiologically tolerable or acceptable diluents, excipients, solvents, adjuvants, or vehicles, for parenteral injection, for intranasal or sublingual delivery, for oral administration,
10 for rectal or topical administration or the like. The compositions are preferably sterile and nonpyrogenic. Examples of suitable carriers include but are not limited to water, saline, dextrose, mannitol, lactose, or other sugars, lecithin, albumin, sodium glutamate cystein hydrochloride, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), vegetable oils (such
15 as olive oil), injectable organic esters such as ethyl oleate, ethoxylated isosteraryl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

The pharmaceutical compositions may also contain minor amounts
20 of nontoxic auxiliary substances such as wetting agents, emulsifying agents, pH buffering agents, antibacterial and antifungal agents (such as parabens, chlorobutanol, phenol, sorbic acid, and the like). If desired, absorption enhancing or delaying agents (such as liposomes, aluminum monostearate, or gelatin) may be used. The compositions can be prepared in conventional forms,
25 either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.

The compositions may be administered by any convenient route which will result in delivery to the blood stream in an amount effective for inhibiting $\alpha 4\beta 1$ - and $\alpha 4\beta 7$ -mediated adhesion, including orally, rectally,
30 parenterally (intravenously, intramuscularly, intraarterially, or subcutaneously),

- 25 -

intracisternally, intravaginally, intraperitoneally, locally (powders, ointments or drops), or as a buccal or nasal spray or aerosol. The compositions can also be delivered through a catheter for local delivery at a target site, or via a biodegradable polymer. The compositions may also be complexed to ligands, or
5 antibodies, for targeted delivery of the compositions.

The compositions are most effectively administered parenterally, preferably intravenously. For intravenous administration, they may be dissolved in any appropriate intravenous delivery vehicle containing physiologically compatible substances, such as sodium chloride, glycine, and the like, having a
10 buffered pH compatible with physiologic conditions. Such intravenous delivery vehicles are known to those skilled in the art. In a preferred embodiment, the vehicle is a sterile saline solution. If the peptides are sufficiently small (*e.g.*, less than about 8-10 amino acids) other preferred routes of administration are intranasal, sublingual, and the like.

15 The compositions according to the invention can be administered in any circumstance in which inhibition of $\alpha 4\beta 1$ and $\alpha 4\beta 7$ integrin function is desirable. Disease states which may be treated include but are not limited to diabetes, multiple sclerosis, rheumatoid arthritis, ulcerative colitis, arteriosclerosis, asthma, allergy, autoimmune disorders, transplant rejection, and
20 restenosis of the arteries following surgery or angioplasty. Because the $\alpha 4$ integrins are expressed on various cancer cells, including leukemia, melanomas, lymphomas, and sarcomas, inhibitors of $\alpha 4$ binding can also be useful in the treatment of some forms of cancer.

The amount of peptide administered depends upon the degree of
25 integrin inhibition that is desired. Those skilled in the art will derive appropriate dosages and schedules of administration to suit the specific circumstances and needs of the patient. Typically, dosages are between about 0.001 mg/kg and about 100 mg/kg body weight. In some embodiments dosages are between about 0.01 mg/kg and about 10 mg/kg body weight. In some embodiments dosages are
30 between about 0.05 mg/kg and about 5 mg/kg body weight.

EXAMPLE 1

A. Materials

A5 and VNRC3 cells, CHO cells transfected with human α Ib β 3 and α v β 3 integrins, respectively (O'Toole *et al.*, *Cell. Regul.* 1:883-893 (1990)), were kindly provided by Dr. M. Ginsberg (Scripps Research Institute, La Jolla, CA). CHO cells with deleted α 5 integrin (B2 cells) were kindly provided by Dr. R. Juliano (University of North Carolina, Chapel Hill, NC). CHO cells transfected with human α 4 and its G190A mutant (Kamata *et al*, *Biochem. J.* 305:945-951 (1995)), and B2 cells transfected with human α 4 (α 4B2) were kindly

- 27 -

provided by dr. Y. Takada (Scripps Research Institute). JY cells expressing $\alpha 4\beta 7$ were a gift of Dr. S. Burakoff (Dana-Farber Cancer Institute, Boston MA) K562 cells transfected with $\alpha 6$ integrin were a gift of Dr. A. Sonnenberg (Netherlands Cancer Institute, Amsterdam, Holland). Jurkat cells, K562 cells,
5 and non transfected CHO-K1 cells were purchased from ATCC (Rockville, MD).

B. Methods

Adhesion of cultured cells labeled with 5-chloromethylfluorescein diacetate (CMFDA) was performed as described earlier (Marcinkiewicz *et al.*, *Blood* **90**:1565-1575 (1997)). Briefly, ligands (such as EC-3, fibrinogen,
10 vitronectin, fibronectin or VCAM-1) were immobilized on 96-well microtiter plate (Falcon, Pittsburgh, PA) in PBS buffer overnight at 4°C. Wells were blocked by 1% BSA in HBSS buffer. Cells were labeled with fluorescein by incubation with 12.5 μ M CMFDA in HBSS buffer containing 1% BSA at 37°C by 15 min. Unbound label was removed by washing with the same buffer.
15 Labeled cells (1×10^5 per sample) were added to the well in the presence or absence of inhibitors and incubated at 37°C for 30 min. Unbound cells were removed by aspiration, the wells were washed and bound cells were lysed by adding 0.5% Triton X-100. In parallel the standard curve was prepared in the same plate from known concentrations of labelled cells. The plate was read using
20 a Cytofluor 2350 fluorescence plate reader (Millipore, Bedford, MA) at 485 nm EX(excitation) filter and 530 nm (emmission) filter.

Determination of the molecular mass of native EC-3 or reduced and alkylated EC-3 subunits was done by electrospray ionization mass spectrometry using a Sciex API-III triple quadrupole instrument.

25 Samples for flow cytometry analysis were prepared as described (Marcinkiewicz *et al.*, *Biochem. J.* **371**:118-124 (1996)), and analyzed in a Coulter Epics flow cytometer (Miami, FL).

The direct binding assay (DBA) with VCAM-1Ig alkaline phosphatase conjugate was performed using Jurkat ($\alpha 4\beta 1$ expressing) and JY

- 28 -

($\alpha 4\beta 7$ expressing) cells according to procedure described in Lobb *et al*, *Cell Adhes. Commun.* 3:385-398 (1995)).

EXAMPLE 2

Identification of *Echis carinatus* Venom Fractions Which Inhibit $\alpha 4\beta 1$

5 Binding to VCAM-1 and $\alpha 5\beta 1$ Binding to Fibronectin

Lyophilized *Echis carinatus suchoreki* venom (obtained from Latoxan Serpentarium, Rosans 05150 France) was dissolved in 0.1% trifluoroacetic acid (10 mg/300 μ l). The solution was centrifuged for 5 minutes at 5000 rpm to remove the insoluble proteins, and the pellet was discarded. The
10 supernatant was applied to a C-18 HPLC column (250 x 10 mm, Vydac TPRP equilibrated in 0.1 % TFA. The column was eluted with an acetonitrile gradient (0-80% over 45 min.) at a flow rate of 2.0 ml/min. As shown in Figure 1, the venom separated into 17 main fractions, which were designated "EC1" through "EC17." EC1 was identified as echistatin (Gan *et al.*, *J. Biol. Chem.* 263:
15 19827-32 (1988)), a strong antagonist of the fibrinogen receptor showing high inhibitory activity ($IC_{50} = 130$ nM) in an ADP-induced platelet aggregation assay. EC10 was identified as echicetin (Peng *et al.*, *Blood* 81:2321-28 (1993)). EC-3 eluted at approximately 40% acetonitrile.

Each eluted fraction was lyophilized, then dissolved in water. The
20 protein concentration in each fraction was estimated using the BCA assay (Pierce). Two μ g of protein from each fraction were immobilized (in separate wells) on a microtiter plate overnight at 4°C in PBS (phosphate buffered saline).

Jurkat cells were labeled by incubation with 12.5 μ M CMFDA (5-chloromethylfluorescein diacetate) in HBSS (Hanks' balanced salt solution) buffer
25 containing 1% BSA (bovine serum albumin) for 15 minutes at 37°C. Cells were washed three times to remove excess CMFDA.

The labeled Jurkat cells were added to the microtiter plate (1×10^5 cells per well), and the plate was incubated for 30 minutes at 37°C. After incubation, unbound cells were removed by aspiration and the wells were washed

- 29 -

three times with HBSS/BSA buffer.

Bound cells were lysed by the addition of 0.5 % Triton X-100, and fluorescence was measured in a Cytofluor 2350 fluorescence plate reader (Millipore) using a 485 nm EX (excitation) filter and a 530 nm EM (emission) filter.

The cells adhered to all fractions except EC4, EC5, and EC8. Fractions with adhesive properties were considered as potential inhibitors of $\alpha 4\beta 1$ binding to VCAM-1 and $\alpha 5\beta 1$ binding to fibronectin.

The cell adhesion assay (as described in Example 1) was used to study the inhibitory effect of the eluted fractions on Jurkat cell adhesion to immobilized VCAM-1 and on K562 cell adhesion to fibronectin. Recombinant VCAM-1 (0.5 μ g/well) or fibronectin (0.5 μ g/well) were immobilized overnight at 4°C on a 96-well plate (Falcon) in PBS buffer. After blocking, the CMFDA-labeled cells were added to each well in the presence of 5 μ g per sample of protein from selected fractions. The results are shown in Fig. 2.

Two fractions, EC3 and EC6, showed significant inhibitory effects on Jurkat cell binding to immobilized VCAM-1. Three fractions: EC1 (echistatin), EC3, and EC6 inhibited binding of K562 cells to immobilized fibronectin. EC3, which eluted at approximately 40% acetonitrile, migrated on SDS-PAGE with an apparent $M_r = 14$ kDa under non reducing conditions and about 7 kDa under reducing conditions, and was relatively free of contaminants.

EXAMPLE 3

Purification of EC-3

The venom fraction eluting at approx. 40% and designated EC3 was purified to homogeneity by two steps of reverse phase HPLC using a C-18 column. In the first step, proteins from crude venom were separated as in Example 2. The column was eluted with an acetonitrile linear gradient 0-80% over 45 minutes, and the EC3 fraction eluting at approximately 40% of acetonitrile was collected, lyophilized, and dissolved in water. The recovery of

- 30 -

protein after the first step was 7 mg per 1 g of dried venom. An aliquot of 0.6 mg of protein isolated in the first step was re-injected into the same HPLC column and eluted with a "flatter" 0-60% acetonitrile gradient over 45 min. The main peak containing EC-3 was collected and lyophilized. The yield of purified EC-3 after the second step was 4 mg per 1g of crude venom. The purity of EC-3 was tested by SDS-PAGE and mass spectrometry. The molecular mass of EC-3, as determined by electrospray ionization mass spectrometry, was $14,762 \pm 1.4$ Da. After reduction, major molecular ions at 7369 Da and 7412 Da were observed.

10

EXAMPLE 4

Characterization of EC-3

A. Subunit Structure

The reduction and alkylation of EC-3 were performed according to a procedure used for trigamin (Huang *et al.*, *J. Biol. Chem.* **262**:16157- 63 (1987)). Briefly, 100 μ g of EC-3 was incubated in 200 μ l of 6 M guanidine hydrochloride, 4 mM EDTA, 0.1 M Tris-HCl, pH 8.5, 3.2 mM dithiothreitol, and 2 μ l of vinyl pyridine. The reaction mixture was incubated for two hours at room temperature in the dark, then applied to a C-18 HPLC column and eluted with an acetonitrile gradient (0-80% over 45 min.). In some experiments EC-3 subunits were reduced and carboxymethylated with iodoacetate acid followed by HPLC separation.

As shown in Figure 3, after reduction and alkylation with vinylpyridine EC-3 separated into two subunits EC3A and EC3B (epEC3A and epEC3B) which eluted at about 42% and 46% acetonitrile respectively. Electrospray ionization mass spectrometry of epEC3A yielded a major ion at 8478 ± 2 Da. The major molecular ion in carboxymethylated EC3B samples had mass 7950 ± 1 Da.

B. Amino Acid Sequence

The N-terminal sequence of native EC-3 electroblotted onto PVDF membrane (Madsudaira, *J. Biol. Chem.* **262**:10035-10038 (1987)) and residues
5 1-40 of epEC3A and epEC3B were determined by N-terminal sequence analysis using an Applied Biosystem Precise instrument. The primary structures of EC-3A and EC-3B were deduced from Edman degradation of overlapping peptides obtained by digestion with endoproteinase Lys-C (Boehringer Mannheim) (2 mg/ml protein in 100 mM ammonium bicarbonate, pH 8.3, for 18 h at 37°C
10 using an enzyme : substrate ratio of 1 : 100 (w/w)) and CNBr (10 mg/ml protein and 100 mg/ml CNBr in 70% formic acid for 6 h under N₂ atmosphere and in the dark). Peptides were separated by reverse-phase of HPLC using a 0.4 x 25 cm Lichrospher RP100 C-18 (5 µm particle size) column (Merck) eluted at 1 ml/min with acetonitrile gradient. For determination of sulfhydryl groups (free
15 cysteines), native EC-3 (2 mg/ml in 100 mM ammonium bicarbonate, pH 8.3 containing 6 M guanidine hydrochloride) was treated for 2 h at room temperature with 100-fold molar excess of iodoacetamide, dialyzed against distilled water, lyophilized and subjected to amino acid analysis (after sample hydrolysis with 6 N HCl for 18 h at 110°C) using a Pharmacia AlphaPlus amino acid analyzer.

20 Analysis of the non reduced EC-3 band excised from the Immobilon-P revealed a single amino acid sequence: NSVHPXXDPV(K/T)XEPREGEHXISGP (SEQ ID NO:1). The complete amino acid sequence of EC3A and EC3B, which is shown in Fig. 4, was determined by N-terminal sequence analysis of reverse phase HPLC-isolated peptides derived
25 from degradation of each subunit with endoproteinase Lys-C and CNBr.

Both, EC3A and EC3B are cysteine-rich proteins of 67 amino acids and display heterogeneity at several positions, indicating the existence of isomorphs (isomorphs are given as SEQ ID NOs:19 and 20; the predicted major isomorphs are given as SEQ ID NOs: 2 and 3). The isotope-averaged molecular
30 masses calculated for the reduced EC3A isomorphs (1-67: N33 I37 G64 E66),

- 32 -

(1-67: R33, V37, G64, E66), and (1-66: N33, I37, D64, D66) are 7412 Da, 7440, Da and 7341 Da, corresponding to major and minor ions of reduced EC-3 mass spectrum. The major EC3A isomorph might be that with molecular weight 7412, which yields a mass of 8476 after reduction and ethylpyridylation. On the other hand, reduced EC3B isomorphs (1-67: T11, K40, S55), (1-67: K11, R40, T55), and (1-67: T11, R40, T55) have calculated masses, 7370 Da, 7439 Da, and 7412 Da, respectively. The major EC3B isomorph, i.e. the one that would have a molecular mass of 7950 after reduction and carboxymethylation, is EC3B 7370 Da. The various EC3A and EC3B isomorphs could combine into a number of dimers. EC3A-EC3B heterodimers may represent the major species, however, because i) homodimers would not yield separated subunits displaying the distinct biological activities demonstrated for HPLC purified A and B fractions, and ii) a mixture of EC3A and EC3B homodimers would display a more complex HPLC separation profile.

As illustrated in Fig. 5, EC3A and EC3B show a high degree of sequence similarity between themselves and with eristostatin (Gould *et al.*, *Proc. Soc. Exp. Biol. Med.* **195**:168-71 (1990)), echistatin (Gan *et al.*, *J. Biol. Chem.* **263**:19827-32 (1988)), flavoridin (Musial *et al.*, *Circulation* **82**:261-73 (1990)), and kistrin (Dennis *et al.*, *Proc. Natl. Acad. Sci. U. S. A.* **87**: 2471-75 (1990)), including alignment of conserved cysteines identified in each subunit. The EC3A amino acid sequence has high homology with the disintegrin domain of Le3, a metalloproteinase-disintegrin identified in *Vipera lebetina* (Siigur *et al.*, *Biochem. Biophys. Res. Commun.* **224**: 229-236 (1996)). Surprisingly, neither EC3 subunit contains an RGD or KGD sequence. This motif is substituted by VGD in EC-3A and by MLD in EC-3B. The hairpin loops in disintegrins described to date are maintained in appropriate conformation by S-S bridges, and the same appears to be true of EC-3. The hair pin loop sequence of echistatin KRARGDDMDDY (SEQ ID NO: 4) is substituted in EC3A and EC3B with KRAVGDDVDDY (SEQ ID NO:5) and KRAMLDGLNDY (SEQ ID NO:6),

- 33 -

respectively. It is likely that the integrin binding sites of EC-3 are located in the two loops encompassing Cys38 to Cys50.

EXAMPLE 5

5

Biological Activities of EC-3

A. Effect of EC-3 on Jurkat Cell Adhesion to Immobilized VCAM-1

The following experiment demonstrated that EC-3 inhibits the adhesion of Jurkat cells to VCAM-1.

Recombinant human VCAM-1 (0.5 μ g/well) was immobilized in the wells of an ELISA plate overnight in PBS buffer. The plate was blocked using HBSS buffer containing 1% BSA. CMFDA-labelled Jurkat cells (1×10^5 cells per sample) were added to the wells in the presence or absence of EC-3 in HBSS buffer containing 1% BSA. The plate was incubated for 30 minutes at 37°C. Unbound cells were removed by aspiration and the wells were washed with HBSS buffer. The bound cells were lysed with 0.5% Triton X-100, and fluorescence was measured. Percent inhibition was calculated by comparing the fluorescence obtained for adhered cells in the absence (0% inhibition) and presence of EC-3. Figure 6 shows the percent inhibition with increasing concentrations of EC-3, in the presence (filled circles) or absence (open circles) of 1 mM Mn^{++} .

15
20

B. Effect of EC-3 on α 4B2 Cell Adhesion to Immobilized VCAM-1

The following experiment demonstrated that EC-3 inhibits the adhesion of Chinese hamster ovary cells, which are α 5 deficient (B2 cells) and have been transfected with human α 4 integrin, to VCAM-1.

25

Chinese hamster ovary cells transfected with human α 4 integrin were provided by Dr. Y. Takada (Scripps Research Institute, La Jolla, CA). Recombinant human VCAM-1 (0.5 μ g/well) was immobilized in the wells of an ELISA plate overnight in PBS buffer. The plate was blocked using HBSS buffer containing 1% BSA. CMFDA-labelled α 4B2 cells (1×10^5 cells per sample)

- 34 -

were added to the wells in the presence or absence of EC-3 in HBSS buffer containing 1% BSA. The plate was incubated for 1 hour at 37°C. Unbound cells were removed by aspiration and the wells were washed with HBSS buffer. The bound cells were lysed with 0.5% Triton X-100, and fluorescence was measured.

5 Figure 7 shows the percent inhibition with increasing concentrations of EC-3.

C. Comparison of the Anti-adhesive Effects of EC-3 and Echistatin

The biological activities of EC3 and the RGD-containing disintegrin echistatin were compared in a panel of integrin assays, the results of which are shown in Figures 6-8 and Table 1.

10 The effect of each peptide on cell adhesion was determined as described above. Briefly, ligands were immobilized on ELISA plates then incubated with cells labeled with CMFDA in the presence of various concentrations of EC-3 or echistatin. Cells that attached to the plates were lysed with detergent, and fluorescence intensity was measured. Percent inhibition was
15 measured at each concentration and IC_{50} was determined.

First, RGD-selective integrins were evaluated. As expected, echistatin at concentrations of 20-130 nM potently inhibited $\alpha IIb\beta 3$ -dependent platelet aggregation and $\alpha IIb\beta 3$ -, $\alpha v\beta 3$ -, and $\alpha 5\beta 1$ -dependent cell adhesion (Table 1). In contrast, EC3 only weakly inhibited $\alpha IIb\beta 3$ -dependent interaction
20 (IC_{50} 1 μM for platelet aggregation and 500 nM for A5 cell adhesion to fibrinogen, respectively) and showed no inhibition of $\alpha v\beta 3$ -dependent adhesion up to 10 μM , although inhibition of $\alpha 5\beta 1$ -dependent adhesion was observed at 150 nM IC_{50} .

TABLE 1

Comparison of the Inhibitory Effects of Echistatin and EC3 on Various Integrins.

Cell suspension	Integrin	Ligand	Assay	Echistatin IC ₅₀ nM	EC3
Platelets	α IIb β 3	Fg	ADP/PA	130	1000
A5 (CHO α IIb β 3+)	α IIb β 3	Fg	CA	50	500
VNRC3 (CHO α v β 3+)	α v β 3	Vn	CA	50	>10 ⁴
K562	α 5 β 1	Fn	CA	20	150
K562 (α 6+)	α 6 β 1	Lm	CA	>10 ⁴	>10 ⁴
A2 (CHO α 4+)	α 4 β 1	VCAM-1	CA	>10 ⁴	30
α 4B2 (CHO- α 4+/ α 5-)	α 4 β 1	VCAM-1	CA	>10 ⁴	30
Jurkat	α 4 β 1	VCAM-1	CA	>10 ⁴	25
Jurkat	α 4 β 1	VCAM-1	DBA	ND	28
Jurkat	α 4 β 1	CS-1	CA	ND	100
JY	α 4 β 7	VCAM-1	DBA	ND	6
RPMI 8866	α 4 β 7	MadCAM-1	CA	>10 ⁴	5

Fg = fibrinogen; Fn = fibronectin; Vn = vitronectin; CS-1 = connective segment 1 of fibronectin; Lm = laminin; PA = platelet aggregation; CA = cell adhesion; DBA = direct binding assay; ND = not determined

- 36 -

When the two disintegrins were evaluated in a panel of $\alpha 4$ integrin cell adhesion assays the specificities were reversed. At concentration of 20-300 nM EC3 was a highly potent inhibitor of the interaction of both anchorage-dependent and anchorage-independent cells expressing $\alpha 4\beta 1$ with either VCAM-1 or the CS-1 fragment of fibronectin, while echistatin showed no detectable activity at 10 μ M. EC3 inhibited to the same extent adhesion of A2 (CHO $\alpha 4 + \alpha 5 +$) cells and $\alpha 4$ B2 (CHO $\alpha 4 + \alpha 5 -$) cells to immobilized VCAM-1, confirming direct inhibition of $\alpha 4\beta 1$ integrin. To further extend the data on $\alpha 4$ integrins, the potency of EC3 in assays measuring VCAM-Ig binding directly to either $\alpha 4\beta 1$ on Jurkat cells or $\alpha 4\beta 7$ on JY cells was evaluated. EC3 potently inhibited $\alpha 4\beta 1$ and $\alpha 4\beta 7$ binding at concentrations 28 nM and 6 nM, respectively. These data both confirm the specificity of EC3 for $\alpha 4$ integrins in an assay distinct from cell adhesion, and show its high potency on integrin $\alpha 4\beta 7$.

D. Effect of HP 2/1 Monoclonal Antibody, GRGDSP (SEQ ID NO:12), and GRGESP (SEQ ID NO:13) Peptides and on Jurkat Cell Adhesion to Immobilized EC-3

Further experiments showed that EC3 competes with mab HP2/1, which recognizes the N-terminal domain of $\alpha 4$ integrin. HP 2/1 at a concentration of 1 μ g per sample blocked adhesion of Jurkat cells to immobilized EC3, whereas the hexapeptide GRGDSP (SEQ ID NO:12) at a concentration of 1 mM was not effective.

Figure 9A shows the effect of GRGDSP (SEQ ID NO:12), GRGESP (SEQ ID NO: 13) and HP 2/1 monoclonal antibody on the adhesion of Jurkat cells to immobilized EC3. The adhesion study was performed using CMFDA-labeled Jurkat cells in the absence or presence 1 mM GRGDSP or GRGESP, or 10 μ g/ml HP 2/1. Competition between EC3 and HP2/1 was also confirmed in cell suspension using FACS analysis. Fig. 9B shows inhibition of HP2/1 binding to $\alpha 4$ B2 cells. The experiment was performed using flow cytometry. Jurkat cells (open bars) or B2-CHO cells (CHO cells with deleted

- 37 -

$\alpha 5$ transfected with $\alpha 4$) (closed bars) were incubated with 10 $\mu\text{g/ml}$ HP 2/1 in the absence (a) or presence 60 nM EC3 (b) for 30 min at room temperature. After washing, 10 $\mu\text{g/ml}$ of FITC-conjugated goat anti-mouse IgG was added and samples were incubated for another 30 min at room temperature. The samples
5 were fixed by addition of 1% paraformaldehyde before measurement of fluorescence intensity. No inhibitory effect was observed in Jurkat cells, which express both $\alpha 5\beta 1$ and $\alpha 4\beta 1$.

Figure 10 shows the adhesion of CHO cells transfected with $\alpha 4$ and with $\alpha 4$ inactive G190A mutant to immobilized EC3 and to immobilized
10 HP2/1 antibody. EC3 (2 $\mu\text{g/well}$) and HP2/1 (1 $\mu\text{g/well}$) were immobilized on the 96-well plate. The CHO cells were labeled with CMFDA and adhesion was performed as described above. The inactive G190A $\alpha 4$ mutant did not interact with EC3, since adhesion of CHO transfected with this mutant to immobilized EC3 was identical with adhesion of non transfected cells. Only A2 cells
15 expressing wild type $\alpha 4$ adhered to immobilized HP2/1. In addition, the ability to inhibit directly $\alpha 5\beta 1$ was confirmed using mab SAM-1, which blocked adhesion of K562 cells to immobilized EC3. Finally, neither echistatin nor EC3 inhibited adhesion to laminin of K562 cells transfected with $\alpha 6$ at concentration 10 μM (see Table 1).

20 E. Platelet Aggregation Assay

Blood from a healthy donor was collected into a syringe containing sodium citrate as an anticoagulant. The anticoagulated blood was centrifuged at 400g for 17 minutes, and platelet rich plasma (PRP) was removed by aspiration. The aggregation of platelets in PRP in the presence of 30 μM ADP was measured
25 in the absence and presence of echistatin and EC-3, using an aggregation meter (Sinco).

Echistatin and EC-3 inhibited ADP induced platelet aggregation with an IC_{50} of 130 nM and 1,000 nM, respectively.

- 38 -

EXAMPLE 6

Biological Activity of EC-3 Peptides

A. Biological Activity of the EC-3 Subunits

The biological activity of EC-3A and EC-3B subunits after
5 reduction and ethylpyridylethylation was also evaluated. Although activity of both
subunits was significant, it was decreased by approximately 200 fold as compared
to EC-3. It has been previously reported that reduction and
ethylpyridylethylation of flavoridin and albolabrin decreased their ability to
inhibit ADP-induced platelet aggregation by 40 fold approximately (Calvete *et*
10 *al.*, *Biochemistry* **30**, 5225-5229 (1991)). As shown in Fig. 11, epEC3B inhibited
adhesion of Jurkat cells to immobilized VCAM-1 with $IC_{50} = 6 \mu M$ whereas
epEC3A was inactive in this system. However, epEC3A and epEC3B both
inhibited adhesion of K562 cells to fibronectin with $IC_{50} = 30 \mu M$ and $6 \mu M$,
respectively. This experiment suggests that the specificity of EC-3 for $\alpha 4$
15 integrins likely resides in the MLD sequence in EC-3B subunit, whereas the
ability of EC-3 to inhibit $\alpha 5 \beta 1$ likely resides in both subunits.

B. Biological Activity of EC-3 Synthetic Peptides

The RGD motif in monomeric disintegrins is replaced by
MLDG (SEQ ID NO:14) in EC-3B. Both RGD and MLDG therefore appear
20 to represent integrin binding sites.

A linear MLDG (SEQ ID NO:14) synthetic peptide was
synthesized using solid phase methodology. As shown in Fig. 12, the linear
MLDG peptide (SEQ ID NO:14) inhibited adhesion of Jurkat cells to
immobilized VCAM-1 with $IC_{50} = 5 \mu M$. An RGDS peptide (SEQ ID NO: 15),
25 which is a known inhibitor of several $\beta 1$ and $\beta 3$ integrins, was inactive at this
concentration.

Two 13-amino acid peptides cyclized through Cys - Cys residues
were synthesized on an automated peptide synthesizer by assembly on 4-
benzyloxybenzyl alcohol resin. Piperidine/toluene were used for removal of the

- 39 -

N^a-9-fluorenylmethyl-oxycarbonyl (Fmoc) group. Neutralization and coupling were carried out in N-methylpyrrolidinone. The benzotriazole-N,N,N',N'-tetramethyl-uronium hexa-fluorophosphate (HBTU)/1-hydroxybenzotriazole-mediated coupling efficiency was determined by a quantitative ninhydrin analysis.

5 Removal of the side-chain protecting groups and cleavage of the assembled peptide from the resin were achieved by treating with trifluoroacetic acid in the presence of ethane dithiol, crystalline phenol, thioanisole and tri-isopropyl silane as scavengers. The peptides were purified using HPLC on C18 column with a water/acetonitrile gradient, containing 0.1 % TFA. The amino acid composition

10 of the peptides was determined by the Pico Tag method, and the molecular mass of the peptides was confirmed using Mass spectrometry.

The cyclic peptide CKRAMLDGLNDYC (Cys Lys Arg Ala Met Leu Asp Gly Leu Asn Asp Tyr Cys, SEQ ID NO:16), representing a putative hair pin loop of EC3B was five fold more active ($IC_{50} = 1$ mM) than MLDG

15 (SEQ ID NO:14) in molar ratio. The cyclic peptide CKRAMLA⁷GLNDYC (SEQ ID NO: 17), in which D⁷ was substituted with alanine, had no significant activity in inhibition of Jurkat cells/VCAM-1 interaction.

Additional peptides, comprising fragments and derivatives of EC-3 such as Met Leu Asp Gly Leu (SEQ ID NO:18), are synthesized and inhibitory

20 activity is measured using assays such as those described in Example 5.

C. Biological Activity of Modified Echistatin Peptides

Using standard methods of recombinant DNA technology, a modified echistatin polypeptide is produced. In the modified echistatin, the Arg-Gly-Asp residues at positions 24-26 are replaced by Met-Leu-Asp. The

25 biological activity of the modified echistatin, as well as fragments and derivatives thereof, is determined.

- 40 -

EXAMPLE 7**Effect of EC-3 on Lymphocyte Infiltration of Langerhans Islets
in Non Obese Diabetic (NOD) Mice****A. The NOD Mouse Model**

5 Lymphocyte extravasation is essential to the normal immune response. Lymphocyte reticulation and accumulation at a site of inflammation is a multistep process which involves interaction between lymphocyte adhesion molecules and their endothelial ligands.

10 Non Obese Diabetic (NOD) mice develop an age related lymphocyte infiltration of pancreatic islets and salivary glands, which resembles human type I diabetes and Sjogren's syndrome. Studies on the adhesion molecules involved in lymphocyte invasion of pancreas and salivary glands in NOD mice have suggested that the integrins $\alpha 4\beta 1$ and $\alpha 4\beta 7$ are important for infiltration of Langerhans islets in the pancreas.

15 The following experiment showed that EC-3, which selectively inhibits $\alpha 4$ integrins, can block lymphocyte invasion of pancreatic parenchyma in NOD mice. Echistatin, which inhibits $\alpha v\beta 3$ - and $\alpha 5\beta 1$ -dependent interactions, but not $\alpha 4$ -dependent interactions, was inactive in this experiment.

20 B. Treatment of Mice

 Female NOD mice from 1 to 5 weeks of age were purchased from Jackson Laboratory (Bar Harbor, ME).

 The mice were divided into 3 groups, and each group was treated with PBS, echistatin, or EC-3 for nine weeks. The PBS, echistatin, and EC-3
25 were administered intraperitoneally in a total volume of 0.5 ml three times per week. The treatment groups were: (a) PBS (control); (b) 1 μg /mouse of echistatin; and (c) 3 μg /mouse of EC-3. The 3 μg /mouse EC-3 dose is the molar equivalent of the 1 μg /mouse echistatin dose, since the molecular weight of EC-3 is approximately three times that of echistatin.

30 After nine weeks of treatment the animals were sacrificed by exposure to CO_2 . The pancreas was removed, frozen, and stored at -70°C until

the histological analysis. For the histological analysis, five μm sections of frozen tissue were fixed with acetone. For detection of infiltrating lymphocytes, the sections were stained with hematoxylin/eosin, and observed by light microscopy.

C. Results

5 The results are shown in Table 2. Treatment with EC-3 reduced the level of lymphocyte infiltration in pancreatic islets of NOD mice, while treatment with echistatin was ineffective.

Table 2

10 **Effect of EC-3 and Echistatin on the Infiltration of Pancreatic Langerhans Islets in NOD Mice**

Group	Number of Animals		Number of Islets				
	Total	without infiltration	Total	Infiltration Score			
				-	+	++	+++
PBS	8	0	25	1	5	10	9
15 Echistatin	10	0	27	5	2	10	10
EC-3	10	2	29	10	12	7	0

infiltration score:

- : no infiltration

+ : periinsular infiltration

20 ++ : $\frac{1}{3}$ of the islet infiltrated

+++ : $\frac{1}{2}$ or more of the islet infiltrated

25 All references discussed herein are incorporated by reference. One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.

CLAIMS**WE CLAIM**

1. A substantially purified EC-3 protein isolated from *E. carinatus* venom, characterized by:
 - 5 (a) an apparent molecular mass of about 14,762 Da, as determined by electrospray ionization mass spectrometry;
 - (b) elution from a C-18 HPLC column at about 40% acetonitrile; and
 - (c) the ability to inhibit adhesion of Jurkat cells to
10 VCAM-1.
2. A substantially purified EC-3A peptide isolated from EC-3 protein which has been reduced and alkylated, characterized by:
 - 15 (a) a molecular mass of about 8478 Da in its ethylpyridylated form, as determined by electrospray ionization mass spectrometry;
 - (b) elution from a C-18 HPLC column at about 42% acetonitrile; and
 - (c) the ability to inhibit adhesion of K562 cells to fibronectin.
- 20 3. A substantially purified EC-3B peptide isolated from EC-3 protein which has been reduced and alkylated with vinylpyridine, characterized by:
 - 25 (a) a molecular mass of about 7950 Da in its carboxymethylated form, as determined by electrospray ionization mass spectrometry;
 - (b) elution from a C-18 HPLC column at about 46% acetonitrile; and
 - (c) the ability to inhibit adhesion of Jurkat cells to VCAM-1.

- 43 -

4. A substantially purified EC-3A peptide comprising the sequence SEQ ID NO:19, or a biologically active fragment or derivative thereof.

5. The peptide of claim 4 comprising the sequence SEQ ID NO: 2.

5 6. A substantially purified EC-3B peptide comprising the sequence SEQ ID NO:20, or a biologically active fragment or derivative thereof.

7. The peptide of claim 6 comprising the sequence SEQ ID NO: 3.

8. A substantially purified EC-3 protein comprising two
10 subunits, wherein one subunit comprises the sequence SEQ ID NO:19 or a biologically active fragment or derivative thereof and one subunit comprises the sequence SEQ ID NO:20 or a biologically active fragment or derivative thereof.

9. A biologically active fragment according to claim 6 having the sequence X-Y-Met-Leu-Asp-Z, where X is H or a blocking group, Y is zero
15 or more amino acids, and Z is OH or zero or more amino acids.

10. A biologically active fragment according to claim 9 wherein said fragment is a peptide having from about 3 to about 20 amino acids.

11. A fragment according to claim 10 having the sequence SEQ ID NO:16.

12. A fragment according to claim 10 having the sequence SEQ ID NO:14.

13. A substantially purified nucleic acid selected from the group consisting of:

(a) nucleic acids encoding the protein or peptide of any of
25 claims 1-12;

(b) nucleic acids hybridizing at high stringency with the nucleic acid in (a); and

(c) nucleic acids derived from (a) or (b) as a result of the degeneracy of the genetic code.

14. A vector comprising the nucleic acid of claim 13.

- 44 -

15. A recombinant cell comprising the nucleic acid of claim 13.
16. An antibody which specifically binds to one of the proteins or peptides of claims 1-12.
17. The antibody of claim 16 wherein said antibody is a
5 monoclonal antibody.
18. A hybridoma that produces the antibody of claim 17.
19. The antibody of claim 16 wherein said antibody is a polyclonal antibody.
20. A substantially purified eichistatin polypeptide in which the
10 Arg-Gly-Asp residues at positions 24-26 are replaced by Met-Leu-Asp, or a biologically active fragment or derivative thereof.
21. A method of isolating a peptide that binds to an integrin of interest from venom comprising:
- (a) dissolving venom in a solvent,
- 15 (b) centrifuging the dissolved venom to remove high molecular weight proteins,
- (c) fractionating the supernatant from step (b),
- (d) immobilizing the fractions from step (c) on a solid support,
- 20 (e) adding detectably labeled cells that express the integrin of interest to the immobilized fractions,
- (f) detecting the number of cells bound to each immobilized fraction, and
- (g) isolating peptide from those fractions which showed
25 enhanced cell binding in step (f).
22. A composition comprising a pharmaceutically acceptable carrier and the protein or peptide of any of claims 1-12, or a pharmaceutically acceptable salt thereof.
23. A composition comprising a pharmaceutically acceptable
30 carrier and the nucleic acid of claim 13.

- 45 -

24. A method of inhibiting the binding of an $\alpha 4$ integrin to VCAM-1 comprising contacting a cell that expresses the $\alpha 4$ integrin with an effective amount of a protein or peptide according to one of claims 1-12, or a pharmaceutically acceptable salt thereof.

5 25. The method of claim 24 wherein the integrin is $\alpha 4\beta 1$ or $\alpha 4\beta 7$.

26. A method of inhibiting the binding of $\alpha 4\beta 7$ integrin to MadCAM-1 comprising contacting a cell that expresses $\alpha 4\beta 7$ with an effective amount of a protein or peptide according to one of claims 1-12, or a pharmaceutically acceptable salt thereof.

10 27. A method of inhibiting the binding of an $\alpha 4$ integrin to CS-1 comprising contacting a cell that expresses the $\alpha 4$ integrin with an effective amount of a protein or peptide according to one of claims 1-12, or a pharmaceutically acceptable salt thereof.

15 28. A method of inhibiting the interaction between cells expressing an $\alpha 4$ integrin and VCAM-1 in a patient in need of such treatment comprising administration of a therapeutically effective amount of a composition according to claim 22.

20 29. A method of inhibiting the interaction between cells expressing an $\alpha 4$ integrin and MadCAM-1 in a patient in need of such treatment comprising administration of a therapeutically effective amount of a composition according to claim 22.


25 30. A method of inhibiting the interaction between cells expressing an $\alpha 4$ integrin and CS-1 in a patient in need of such treatment comprising administration of a therapeutically effective amount of a composition according to claim 22.

- 46 -

31. A substantially purified EC-3A peptide characterized by:
(a) a sequence having substantial homology with SEQ ID
NO:2; and
(b) the ability to inhibit adhesion of K562 cells to
5 fibronectin.
32. A substantially purified EC-3B peptide characterized by:
(a) a sequence having substantial homology with SEQ ID
NO:3; and
(b) the ability to inhibit adhesion of Jurkat cells to VCAM-
10 1.
33. A substantially purified nucleic acid selected from the
group consisting of:
(a) nucleic acids encoding the peptide of claims 31 or 32;
(b) nucleic acids hybridizing at high stringency with the
15 nucleic acid in (a); and
(c) nucleic acids derived from (a) or (b) as a result of the
degeneracy of the genetic code.

1/12

Fig. 1



THIS PAGE BLANK (USPTO)

2/12

Fig.
2B





Fig.
2A



THIS PAGE BLANK (USPTO)




Fig. 3

THIS PAGE BLANK (USPTO)

1 10 20 30 40 50 60
 NSVHPCCDPVKCEPREGEHCISGPPCCRNCFYFLRAGTVCKRAVGDDVDDYCSGITPDCPRNRYKGGKED
 |----- N-terminal sequencing -----
 |----- K3 -----
 |----- K5 -----
 |----- K1a -----
 |----- K2 -----
 |----- K4 -----
 D D

Fig. 4A

1 10 20 30 40 50 60
 NSVHPCCDPVKCEPREGEHCISGPPCCRNCKFLNAGTICKRAMLDGLNDYCTGISTDCPRNRYKGGKED
 T
 |----- N-terminal sequencing -----
 |----- CNBr-1 -----
 |----- K1 -----
 |----- T K7 -----
 |----- K6 -----
 |----- K10a -----
 |----- K4 -----
 |----- K10b -----
 S

Fig. 4B

THIS PAGE BLANK (USPTO)




Fig. 5

THIS PAGE BLANK (USPTO)




Fig. 6

THIS PAGE BLANK (USPTO)





Fig. 7

THIS PAGE BLANK (USPTO)

8/12

Fig. 8



THIS PAGE BLANK (USPTO)

9/12

Fig. 9B





Fig. 9A



THIS PAGE BLANK (USPTO)

10/12




Fig. 10

THIS PAGE BLANK (USPTO)

11/12

Fig. 11B





Fig. 11A



THIS PAGE BLANK (USPTO)

12/12




Fig. 12

THIS PAGE BLANK (USPTO)

SEQUENCE LISTING

<110> Niewiarowski, Stefan
 Marcinkiewicz, Cezary
 Temple University, of the Commonwealth System of Higher Education

<120> EC-3, An Inhibitor of Alpha 4 Beta 1 and Alpha 4 Beta 7
 Integrins

<130> 6056-236PC

<140>

<141>

<150> 60/055,825

<151> 1997-08-15

<150> 60/055,957

<151> 1997-08-18

<160> 20

<170> PatentIn Ver. 2.0

<210> 1

<211> 24

<212> PRT

<213> Echis carinatus

<220>

<221> VARIANT

<222> (11)

<223> K or T

<400> 1

Asn	Ser	Val	His	Pro	Xaa	Xaa	Asp	Pro	Val	Xaa	Xaa	Glu	Pro	Arg	Glu
1				5					10					15	

Gly	Glu	His	Xaa	Ile	Ser	Gly	Pro
				20			

<210> 2

<211> 67

<212> PRT

<213> Echis carinatus

<400> 2

THIS PAGE BLANK (USPTO)

Asn Ser Val His Pro Cys Cys Asp Pro Val Lys Cys Glu Pro Arg Glu
 1 5 10 15

Gly Glu His Cys Ile Ser Gly Pro Cys Cys Arg Asn Cys Tyr Phe Leu
 20 25 30

Arg Ala Gly Thr Val Cys Lys Arg Ala Val Gly Asp Asp Val Asp Asp
 35 40 45

Tyr Cys Ser Gly Ile Thr Pro Asp Cys Pro Arg Asn Arg Tyr Lys Gly
 50 55 60

Lys Glu Asp
 65

<210> 3

<211> 67

<212> PRT

<213> *Echis carinatus*

<400> 3

Asn Ser Val His Pro Cys Cys Asp Pro Val Lys Cys Glu Pro Arg Glu
 1 5 10 15

Gly Glu His Cys Ile Ser Gly Pro Cys Cys Arg Asn Cys Lys Phe Leu
 20 25 30

Asn Ala Gly Thr Ile Cys Lys Arg Ala Met Leu Asp Gly Leu Asn Asp
 35 40 45

Tyr Cys Thr Gly Ile Ser Thr Asp Cys Pro Arg Asn Arg Tyr Lys Gly
 50 55 60

Lys Glu Asp
 65

<210> 4

<211> 11

<212> PRT

<213> *Echis carinatus*

<400> 4

Lys Arg Ala Arg Gly Asp Asp Met Asp Asp Tyr
 1 5 10

THIS PAGE BLANK (USPTO)

<210> 5

<211> 11

<212> PRT

<213> Echis carinatus

<400> 5

Lys Arg Ala Val Gly Asp Asp Val Asp Asp Tyr

1

5

10

<210> 6

<211> 11

<212> PRT

<213> Echis carinatus

<400> 6

Lys Arg Ala Met Leu Asp Gly Leu Asn Asp Tyr

1

5

10

<210> 7

<211> 64

<212> PRT

<213> Vipera lebetina

<400> 7

Asn Ser Gly Asn Pro Cys Cys Asp Pro Val Thr Cys Gln Pro Arg Arg

1

5

10

15

Gly Glu His Cys Val Ser Gly Lys Cys Cys Arg Asn Cys Lys Phe Leu

20

25

30

Arg Ala Gly Thr Val Cys Lys Arg Ala Val Gly Asp Asp Met Asp Asp

35

40

45

Tyr Cys Thr Gly Ile Ser Ser Asp Cys Pro Arg Asn Pro Tyr Lys Asp

50

55

60

<210> 8

<211> 49

<212> PRT

<213> Eristocophis macmah nii

<400> 8

THIS PAGE BLANK (USPTO)

Gln Glu Glu Pro Cys Ala Thr Gly Pro Cys Cys Arg Arg Cys Lys Phe
 1 5 10 15

Lys Arg Ala Gly Lys Val Cys Arg Val Ala Arg Gly Asp Trp Asn Asp
 20 25 30

Asp Tyr Cys Thr Gly Lys Ser Cys Asp Cys Pro Arg Asn Pro Trp Asn
 35 40 45

Gly

<210> 9

<211> 49

<212> PRT

<213> *Echis carinatus*

<400> 9

Glu Cys Glu Ser Gly Pro Cys Cys Arg Asn Cys Lys Phe Leu Lys Glu
 1 5 10 15

Gly Thr Ile Cys Lys Arg Ala Arg Gly Asp Asp Met Asp Asp Tyr Cys
 20 25 30

Asn Gly Lys Thr Cys Asp Cys Pro Arg Asn Pro His Lys Gly Pro Ala
 35 40 45

Thr

<210> 10

<211> 70

<212> PRT

<213> *Trimeresurus flavoviridis*

<400> 10

Gly Glu Glu Cys Asp Cys Gly Ser Pro Ser Asn Pro Cys Cys Asp Ala
 1 5 10 15

Ala Thr Cys Lys Leu Arg Pro Gly Ala Gln Cys Ala Asp Gly Leu Cys
 20 25 30

Cys Asp Gln Cys Arg Ph Lys Lys Lys Thr Gly Ile Cys Arg Ile Ala
 35 40 45

Arg Gly Asp Phe Pro Asp Asp Arg Cys Thr Gly Leu Ser Asn Asp Cys

THIS PAGE BLANK (USPTO)

50

55

60

Pro Arg Trp Asn Asp Leu
65 70

<210> 11
<211> 68
<212> PRT
<213> Calloselasma rhodostoma

<400> 11
Gly Lys Glu Cys Asp Cys Ser Ser Pro Glu Asn Pro Cys Cys Asp Asp
1 5 10 15

Ala Thr Cys Lys Leu Arg Pro Gly Ala Gln Cys Gly Glu Gly Leu Cys
20 25 30

Cys Glu Gln Cys Lys Phe Ser Arg Ala Gly Lys Ile Cys Arg Ile Pro
35 40 45

Arg Gly Asp Met Pro Asp Asp Arg Cys Thr Gly Gln Ser Ala Asp Cys
50 55 60

Pro Arg Tyr His
65

<210> 12
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
peptide

<400> 12
Gly Arg Gly Asp Ser Pro
1 5

<210> 13
<211> 6
<212> PRT
<213> Artificial Sequence

<220>

THIS PAGE BLANK (USPTO)

<223> Description of Artificial Sequence: synthetic peptide

<400> 13

Gly Arg Gly Glu Ser Pro

1

5

<210> 14

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic peptide

<400> 14

Met Leu Asp Gly

1

<210> 15

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic peptide

<400> 15

Arg Gly Asp Ser

1

<210> 16

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic peptide

<220>

<221> DISULFID

<222> (1) .. (13)

THIS PAGE BLANK (USPTO)

<400> 16

Cys Lys Arg Ala Met Leu Asp Gly Leu Asn Asp Tyr Cys
1 5 10

<210> 17

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
peptide

<220>

<221> DISULFID

<222> (1)..(13)

<400> 17

Cys Lys Arg Ala Met Leu Ala Gly Leu Asn Asp Tyr Cys
1 5 10

<210> 18

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
peptide

<400> 18

Met Leu Asp Gly Leu
1 5

<210> 19

<211> 67

<212> PRT

<213> Echis carinatus

<220>

<221> VARIANT

<222> (33)

<223> R or N

THIS PAGE BLANK (USPTO)

<220>

<221> VARIANT

<222> (37)

<223> V or I

<220>

<221> VARIANT

<222> (64)

<223> G or D

<220>

<221> VARIANT

<222> (66)

<223> E or D

<400> 19

Asn	Ser	Val	His	Pro	Cys	Cys	Asp	Pro	Val	Lys	Cys	Glu	Pro	Arg	Glu
1				5					10					15	

Gly	Glu	His	Cys	Ile	Ser	Gly	Pro	Cys	Cys	Arg	Asn	Cys	Tyr	Phe	Leu
			20					25					30		

Xaa	Ala	Gly	Thr	Xaa	Cys	Lys	Arg	Ala	Val	Gly	Asp	Asp	Val	Asp	Asp
			35					40					45		

Tyr	Cys	Ser	Gly	Ile	Thr	Pro	Asp	Cys	Pro	Arg	Asn	Arg	Tyr	Lys	Xaa
	50						55					60			

Lys	Xaa	Asp
65		

<210> 20

<211> 67

<212> PRT

<213> Echis carinatus

<220>

<221> VARIANT

<222> (11)

<223> K or T

<220>

<221> VARIANT

<222> (40)

<223> R or K

<220>

THIS PAGE BLANK (USPTO)

<221> VARIANT

<222> (55)

<223> T or S

<400> 20

Asn Ser Val His Pro Cys Cys Asp Pro Val Xaa Cys Glu Pro Arg Glu

1

5

10

15

Gly Glu His Cys Ile Ser Gly Pro Cys Cys Arg Asn Cys Lys Phe Leu

20

25

30

Asn Ala Gly Thr Ile Cys Lys Xaa Ala Met Leu Asp Gly Leu Asn Asp

35

40

45

Tyr Cys Thr Gly Ile Ser Xaa Asp Cys Pro Arg Asn Arg Tyr Lys Gly

50

55

60

Lys Glu Asp

65

THIS PAGE BLANK (USPTO)

PATENT

Attorney Docket No.: 6056-236 PC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACTING AS THE RECEIVING OFFICE

In re: Patent application of	:	
Temple University - Of The Commonwealth	:	Group Art Unit:
System of Higher Education et al.	:	1652
	:	
International Application No.:	:	
PCT/US98/16719	:	Examiner:
	:	G. Bugaisky
International Filing Date:	:	
13 August 1996	:	
	:	
For: EC3, AN INHIBITOR OF ALPHA4 BETA 1	:	
AND ALPHA4 BETA7 INTEGRINS	:	

Assistant Commissioner of Patents
BOX PCT
Washington, D.C. 20231
ATTENTION: PCT LEGAL

**REQUEST FOR RECTIFICATION OF OBVIOUS ERROR
IN INTERNATIONAL APPLICATION (PCT Rule 91.1)**

This is in response to the Invitation to Correct The Purported International Application mailed September 29, 1998.

The Invitation To Correct states that the application does not contain the designation of at least one contracting state pursuant to Rule 4.9(a). It is alleged that applicants' Request (Form PCT/RO/101) filed with the international application on August 13, 1998 failed to include a page containing a Designation of States. The Invitation To

CERTIFICATE OF TRANSMISSION	
I hereby certify that this paper is being transmitted by facsimile to the United States Patent and Trademark Office on the date shown below.	
BY	<u>Coleen Ryan</u>
DATE:	<u>10-1-98</u>

THIS PAGE BLANK (USPTO)

Correct further states that, as a result of the omission, the international filing date of the application will be the date on which the appropriate corrections are received. Upon being notified of the defect, applicants took immediate corrective measures by submitting a completed Designation of States page (designating all member states, including the United States) on September 29, 1998.

Applicants submit that the omission of a Designation of States page with the international application on August 13 should be treated as an obvious error in the Request form. For the reasons that follow, rectification should be permitted so as to treat the international application *as filed on August 13, 1998* with a designation of *all* states, including the United States.

PCT Rule 91.1 "*Rectification*" provides that errors which are due to the fact that something other than was obviously intended was written in the international application *or other paper* shall be regarded as obvious errors. Rule 91.1 further provides that the rectification itself shall be obvious "in the sense that anyone would immediately realize that nothing else could have been intended than what is offered as rectification."

Applicants' Request filed August 13 included an identification of three applicants: (i) Temple University - Of The Commonwealth System of Higher Education (hereinafter "Temple University"; Box No. II), (ii) Stefan Niewiarowski (hereinafter "Niewiarowski"; Box No. III) and (iii) Cezary Marcinkiewicz (hereinafter "Marcinkiewicz"; Continuation of Box No. III). At the foot of Box II, Temple University is identified as the applicant for purposes of "all designated States except the United States of America". Hence, it is plainly apparent that applicants meant to designate one or more states *other than* the United States. At the foot of Box III and the continued Box III, Niewiarowski and

THIS PAGE BLANK (USPTO)

Marcinkiewicz are identified as applicants for purposes of "the United States of America only". Hence, it is plain that applicants meant to designate the United States.

In completing the PCT Calculation Sheet applicants listed the number of designation fees paid as "11", the maximum number permitted. The payment of the maximum designation fee (\$1155) is entirely consistent with applicants' clear intention *at the time of the filing of the international application* to designate all member states. Of course, one would not expect an applicant to pay the maximum designation fee for just eleven designations, since the twelfth and further designations are free. Applicants who pay for eleven designations invariably elect *all* member states. Moreover, the Receiving Office accepted "the payment of all prescribed fees", including the designation fee. See the Notification Concerning Payment of Prescribed Fees mailed September 15, 1998. The maximum designation fee of \$1155 was in fact charged to the deposit account of applicants' attorney on August 20, 1998, as evidenced by Exhibit 1 hereto.

From the totality of the Request form and the PCT Calculation Sheet filed with the international application, it is plainly apparent that the omission of explicit country designations is an obvious error rectifiable under Rule 91.1. Anyone versed in the formalities of PCT practice would immediately recognize that nothing else could have been intended by applicants other than a complete designation of all PCT member states, including the United States.

Rectification is respectfully requested to accept designation of all PCT member states, inclusive of the United States, retroactive to the original international filing date of August 13, 1998. Restoration of that filing date is requested, with complete entitlement to the Paris Convention priority of applications USSN 60/055,825 and

THIS PAGE BLANK (USPTO)

60/055,957, filed respectively on August 15 and 18, 1997. This request is being made before the expiration of 17 months from the earliest claimed priority date.

No fee is believed due for the consideration of this request. However, if a fee is due, please charge deposit account 19-1135.

Respectfully submitted,

TEMPLE UNIVERSITY- OF
THE COMMONWEALTH SYSTEM
OF HIGHER EDUCATION, et al.

By: *Daniel A. Monaco*

DANIEL A. MONACO

Registration No. 30,480

SEIDEL, GONDA, LAVORGNA
& MONACO, P.C.

Suite 1800, Two Penn Center Plaza

Philadelphia, PA 19102

Telephone: (215) 568-8383


Facsimile: (215) 568-5549

Attorney for Applicants

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/16719

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : Please See Extra Sheet. US CL : Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/7.21, 334, 325, 331, 252.3, 320.1; 530/324, 326, 327, 328, 329, 344, 350, 387.9, 388.2, 412, 415, 856; 536/23.5 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SIIGUR et al. cDNA Cloning and Deduced Amino Acid Sequence of Fibrinolytic Enzyme (Lebetase) from Vipera lebetina Snake Venom. Biochemical and Biophysical Research Communications. 1996, Vol. 224, No. 1, pages 229-336, especially figure 2.	1-15, 20, 22-23, 31-33
A	US 5,318,899 A (SCARBOROUGH et al.) 07 June 1994, entire document.	1-33
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *G* document member of the same patent family	
Date of the actual completion of the international search 06 NOVEMBER 1998		Date of mailing of the international search report 31 DEC 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized Officer  GABRIELE E. BUGAISKY Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/16719

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

A61K 38/04, 38/17, 48/00; C07K 1/36, 4/12, 5/08, 5/10, 7/04, 14/46, 16/18; C12N 1/00, 5/10, 5/12, 15/12, 15/63; G01N 33/50

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

435/7.21, 334, 325, 252.3, 320.1; 530/324, 326, 327, 328, 329, 344, 350, 387.9, 412, 415; 536/23.5

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN-CAS files registry, caplus, medline, wpids; A-Geneseq32, PIR56; SWISS-PROT35
search terms: Echis, coloratus, integrin?, alpha4, alpha 4, CS1, CS 1, MadCam, disintegrin?, screen?, echistatin, venom?, substitut?, mutat?, mutan?, jurkat, v cam, 66aa, 67aa, (66 or 67)(w)(amino acids or aa), nsvhpcdpv/sqsp, hpccdpv/sqsp, peptide?, viper, snake